

THE ROLE OF VOLTAGE MAPPING AND CARDIAC CT ANGIOGRAPHY IN PATIENTS UNDERGOING ABLATION FOR ATRIAL FIBRILLATION

PhD thesis

Szilvia Herczeg MD

Doctoral School of Theoretical and Translational Medicine
Semmelweis University



Supervisor: László Gellér, MD, Ph.D.

Official reviewers: Zoltán Imre Pozsonyi, MD, Ph.D.

Péter Kupó, MD, Ph.D.

Head of the Complex Examination Committee: Tivadar Tulassay MD, D.Sc.

Members of the Complex Examination Committee: Péter Andréka MD, Ph.D.

Attila Patócs MD, Ph.D.

Budapest

2022

TABLE OF CONTENT

List of Abbreviations	5
1. Introduction	6
1.1. Atrial fibrillation (AF).....	6
1.1.1. The definition of AF.....	6
1.1.2. Significance of AF	6
1.1.3. Treatment of AF	6
1.1.4. Catheter ablation for AF.....	7
1.1.5. Success of catheter ablation and its risk factors	10
1.2. Atrial fibrosis.....	11
1.2.1. Significance of atrial fibrosis	11
1.2.2. Quantification of atrial fibrosis	12
1.2.2.1. MRI and atrial fibrosis	12
1.2.2.2. Voltage mapping	13
1.2.3. Low voltage area as target for ablation	15
1.3. The peri-ablation role of cardiac CT angiography	16
2. Objectives	18
2.1. Atrial low voltage area	18
2.2. Coronary artery disease	18
3. Methods	19
3.1. Quantification and risk factors of atrial low voltage area and its relationship with the success rate of AF ablation.....	19
3.1.1. Study population	19
3.1.2. Ablation and HD electro-anatomical mapping.....	19
3.1.3. Voltage map offline analysis.....	20
3.1.4. Measurement of atrial dimensions	21
3.1.5. Follow-up	21
3.2. Obstructive coronary artery disease in patients with AF	22
3.2.1. Study population	22
3.2.2. Coronary CT angiography and image analysis	22
3.3. Statistical analysis	23

4. Results	24
4.1. Quantification and risk factors of atrial low voltage area and its relationship with the success rate of AF ablation.....	24
4.1.1. Quantitative assessment of left atrial low voltage area	24
4.1.1.1. Patient demographics and distribution of left atrial low voltage area.....	24
4.1.1.2. Relationship of Diseased LA Tissue burden and patient characteristics.....	25
4.1.2. Right Atrial Diseased Tissue burden in the prediction of Left Atrial Diseased Tissue burden	28
4.1.2.1. Patient and procedure characteristics	28
4.1.2.2. Relationship of Diseased RA Tissue and baseline characteristics	29
4.1.2.3. Correlation between Diseased RA and LA Tissue	30
4.1.3. Predictive value of left atrial low voltage area for the outcome of ablation	31
4.1.3.1. Patient and procedure characteristics	31
4.1.3.2. Follow-up results and overall success rates	32
4.1.3.3. Predictors of recurrence	34
4.2. Obstructive coronary artery disease in patients with AF	36
4.2.1. Patient characteristics	36
4.2.2. Comparison of patients with and without any chest pain.....	37
4.2.3. Coronary artery status of the studied population	38
5. Discussion	40
5.1. Voltage mapping and its role in patients with AF.....	40
5.1.1. Technical variances of voltage mapping	40
5.1.2. Risk factors of low voltage area	41
5.1.3. Predictive role of low voltage area.....	43
5.1.4. Biatrial low voltage area	44
5.2. The role of pre-ablation coronary CT angiography in AF patients	45
5.2.1. Relationship of chest pain and coronary artery disease in AF patients.....	45
5.2.2. Technical variances of coronary artery disease diagnostics with CT	46
5.2.3. Risk factors of coronary artery disease	47
5.2.4. Clinical impact of pre-ablation coronary CT angiography	47
6. Limitations.....	49

7. Conclusions	50
8. Summary	52
9. Összefoglalás	53
10. References	54
11. Bibliography of the candidate's publication	79
11.1. Bibliography related to the present thesis	79
11.2. Bibliography not related to the present thesis	79
12. Acknowledgements	82

LIST OF ABBREVIATIONS

AAD	Antiarrhythmic Drug	ICE	Intracardiac
AF	Atrial Fibrillation		Echocardiography
BIFA	Box Isolation of the Fibrotic Area	LA	Left Atrium/Atrial
BMI	Body Mass Index	LAV(I)	Left Atrial Volume (Index)
BNP	B-type Natriuretic Peptide	LGE-MRI	Late Gadolinium Enhancement MRI
BSA	Body Surface Area	LVA	Low Voltage Area
CA	Catheter Ablation	LVEF	Left Ventricular Ejection Fraction
CAC(S)	Coronary Artery Calcium (Score)	MRI	Cardiac Magnetic Resonance Imaging
CAD	Coronary Artery Disease	NOAC	Non Vitamin K Antagonist Oral Anticoagulant
CT(A)	Computed Tomography (Angiography)	NT-proBNP	N-terminal Prohormone BNP
CV	Cardiovascular	PV	Pulmonary Vein
(DE)-MRI	(Delayed Enhancement) Magnetic Resonance Imaging	PVI	Pulmonary Vein Isolation
EAM	Electro-anatomical Map(ping)	QoL	Quality of Life
EAMS	Electro-anatomical Mapping System	RA	Right Atrium/Atrial
EP	Electrophysiology	RAV(I)	Right Atrial Volume (Index)
FACM	Fibrotic Atrial Cardiomyopathy	SR	Sinus Rhythm
HD	High-Density	TOE	Transoesophageal Echocardiography
HFrEF	Heart Failure with reduced Ejection Fraction	VHA	Voltage Histogram Analysis
		VKA	Vitamin K Antagonist

1. INTRODUCTION

1.1. ATRIAL FIBRILLATION (AF)

1.1.1. *THE DEFINITION OF AF*

Atrial fibrillation (AF) is an irregular supraventricular tachycardia with ineffective atrial contraction due to uncoordinated atrial electrical activation. Diagnosis of AF is mainly made by a 12-lead electrocardiogram (ECG), which shows irregular R-R intervals (in case of no atrioventricular conduction impairment), absence of P waves, and irregular atrial activation ('f' waves). An episode of AF lasting ≥ 30 seconds is diagnostic for clinical AF. Symptoms of AF may range from none to disabling: including palpitation, shortness of breath, chest discomfort, and fatigue (1).

Traditionally the following patterns of AF are distinguished (1):

- first diagnosed: AF not known before
- paroxysmal: AF terminating spontaneously or by intervention within 7 days of onset
- persistent: sustained AF beyond 7 days of onset
- long-standing persistent: continuous AF of more than 12 months' duration with rhythm control strategy
- permanent: continuous AF with frequency control strategy

1.1.2. *SIGNIFICANCE OF AF*

AF is the most common cardiac arrhythmia in our population: the lifetime AF risk is estimated to be one out of three individuals of European ancestry at index age of 55 years, affecting globally 43.6 million people with a continuously rising prevalence (1-4). AF is associated with ischaemic stroke, heart failure, a decrease in cognitive function, lower quality of life (QoL), extended medical costs, as well as increased mortality (5). Therefore, risk stratification, primary and secondary prevention, and the development of effective treatments for AF are crucial (1).

1.1.3. *TREATMENT OF AF*

The treatment of AF requires an integrated management: the holistic 'ABC' pathway is suggested by the European Society of Cardiology's latest prevention guideline (6). Anticoagulation for avoiding stroke ('A'), better symptom management ('B'), and cardiovascular (CV) and comorbidity optimization ('C') (6).

In general, anticoagulation is recommended for AF patients with elevated thromboembolic risk score, estimated by CHA₂DS₂-VASc score (1). This score involves the following risk factors: Congestive heart failure, Hypertension, Age, Diabetes, Stroke/transient ischemic attack/thromboembolism, Vascular disease, and female Sex (7). The most commonly used oral anticoagulants are distinguished into two groups: K-vitamin antagonists (VKA, e.g. acenocoumarol, warfarin) and non-vitamin K antagonist oral anticoagulant (NOAC, e.g. rivaroxaban, apixaban, edoxaban, dabigatran) (8).

Better symptom control helps to improve AF-related symptoms with rate control and/or rhythm control therapy. Rate control therapy can be achieved with different medications (e.g. beta-blockers, digoxin, diltiazem and verapamil), targeting < 110 beats per minute and AF-related symptom release. Another definitive solution for rate control is pacemaker implantation and ablation of the atrioventricular node; mainly used for severely symptomatic patients with permanent AF. Rhythm control strategy refers to attempts to restore and maintain sinus rhythm, which could be used in combination. These treatments include electrical or pharmacological cardioversion, antiarrhythmic drug (AAD) administration (e.g. amiodarone, dronedarone, flecainide, propafenone, sotalol), catheter ablation, and surgical cure with maze procedure (1). Early rhythm control therapy for AF improves not just QoL, but also leads to the reduction of CV death, stroke, or hospitalization in symptomatic and asymptomatic AF patients (9).

The ‘C’ component of the pathway includes identification and management of concomitant diseases and cardiometabolic risk factors (e.g. hypertension, diabetes, obstructive sleep apnoea, heart failure, coronary artery disease, obesity), and unhealthy lifestyle factors (e.g. alcohol use, physical inactivity). Targeted therapy of underlying conditions and modification of risk factors may improve the success of rhythm control therapy (1).

1.1.4. *CATHETER ABLATION FOR AF*

Catheter ablation (CA) is a well-established rhythm control therapy for AF (5, 10). Its main benefit is the improvement of QoL with a long-term recurrence-free, asymptomatic period, significant reduction of CV hospitalizations, lowering antiarrhythmic drug utilization and prescription drug expenditures as well (11-14).

The aim of CA is to eliminate the arrhythmogenic substrate, most commonly found around the ostia of pulmonary veins (PV) in the left atrium (LA) (15). Pappone et al. developed the method of pulmonary vein isolation (PVI), where a persistent electrical disconnection is performed between the PVs and the LA (16). For isolation, radiofrequency or cryo energy-based ablation catheters are used, inserted percutaneously from the femoral vein, guided transseptal to the LA. The ablation catheter creates an electrically non-conducting, transmural myocardial scar establishing sinus rhythm (17). The radiofrequency-generated heat can be transmitted from an irrigated ablation catheter using point-by-point ablation technique or a multi-electrode circular ablation catheter using single-shot ablation technique. One of the most common used technique is the wide antral circumferential ablation (WACA) point-by point strategy, where wider continuous circumferential ablation lesions are created around the left and right PVs (Figure 1) (16). Upon the investigators' discretion, additional atrial substrates may be targeted, however, its additional benefit is still controversial, thus it is recommended rather in specific cases (18-22). On the other hand, the cryoballoon ablation system, being a single-shot ablation approach, creates electrical isolation around each pulmonary veins' ostia by freezing the targeted area (5). The non-inferiority of cryoballoon ablation compared to radiofrequency point by point CA was proved in the "FIRE AND ICE" multicentre randomized clinical trial (23).

Different imaging technologies help the investigator to precisely tailor the ablation strategy and give guidance during the procedure. A pre-procedural cardiac computed tomography angiography (CTA) or cardiac magnetic resonance imaging (MRI) gives detailed information about the anatomy of the LA and PVs. The integration of those images with the procedurally created electro-anatomical map (EAM) using multipolar catheters, creates a detailed and accurate 3D map of the targeted area. Catheter movement and ablation can be guided by fluoroscopy, transoesophageal echocardiography (TOE), intracardiac echocardiography (ICE), and the EAM System (EAMS) (5, 24).




Figure 1. Pulmonary vein isolation projected on left atrial fast anatomic map (postero-anterior view, CARTO 3® platform) – ablation points are marked with red dots (Image of our working group)

CA might be a first-line therapy for AF patients with heart failure with reduced ejection fraction (HFrEF) (Class I indication), for symptomatic paroxysmal AF patients (Class IIa), and for symptomatic persistent AF patients without major risk factors for recurrence (Class IIb) (considering the patients' choice as well). In special conditions, CA could be considered a first-line therapy for patients with persistent AF and major risk factors for AF recurrence. Additionally, if the AAD therapy fails, CA should be considered as second-line for the paroxysmal, and persistent AF population (Class I), and for the individuals with HFrEF (Class IIa).

The alternative to CA for rhythm control is AAD therapy, which can be considered as first-line therapy for every AF patient based on their choice (1). Still, multiple studies proved longer arrhythmia-free rates and improvement in QoL after CA compared to the AAD approach (25-30). However, besides the improvement in symptoms and AF burden, no prospective and randomized trial have showed other benefits favouring CA vs AAD yet (1). In the most awaited CABANA trial, including more than two thousand patients, no significant reduction was presented in mortality, disabling stroke, serious bleeding, or cardiac arrest after CA compared to AAD therapy (30, 31). Based on the above, the current guideline recommends CA only for symptomatic AF patients (1). Nevertheless, the recent EAST-AFNET 4 trial involving over five thousand patients revealed that there was no significant difference in the effect of rhythm control therapy (including CA in about a quarter of the patients) in asymptomatic AF patients compared to symptomatic

ones. Thus, these findings suggest the favour of an early rhythm control therapy independent from AF symptoms (9). Hybrid AAD and CA are both accepted and often-used strategies, while AADs started or continued after CA may reduce AF recurrence (32-34).

1.1.5. *SUCCESS OF CATHETER ABLATION AND ITS RISK FACTORS*

The arrhythmia-free outcome of CA is superior to AADs, however, significant recurrence is still observed after the procedure. Early recurrence, defined as > 30 seconds of atrial tachyarrhythmia during the first 3 months after CA (blanking period), has been observed in 27-52% of the studied patients (5, 35-38). Early recurrence does not mean the failure of ablation therapy, but it is often considered as a predictor of long-term recurrence (36, 39, 40). Long-term recurrence is defined as > 30 seconds of atrial tachyarrhythmia after the 3 months long blanking period (5). The causes of recurrence could be in general microreentrant tachycardia due to the reconnection of PVs, non-PV dependent macroreentrant tachycardia (e.g. mitral isthmus dependent), or intrinsic/iatrogenic atrial scarring (5, 41). The single procedure one-year success rate has varied between 40-94 % (5, 42-45), the two-year success rate has been reported around 45-85% (11, 25, 46, 47), at 5 years it has been around 20-84% (5, 48-51), and some studies have observed 31-73% success rates after 10 years of follow-up (5, 52, 53). With multiple ablations, these numbers improve significantly to 52-80 % (47, 48, 51, 54, 55). However, the listed studies are hardly comparable due to different ablation techniques, types of AF, and comorbidities of the patients.

Nevertheless, the particularly variable success rates highlight the importance of different risk factors associated with AF recurrence. Additionally, they underline the relevance of wise patient selection, as well as the effective control of modifiable risk factors to maintain sinus rhythm after CA (1, 56, 57). The detailed introduction of these factors exceeds the scope of the current dissertation, therefore only the most common parameters are listed hereinafter. The expected success rates of CA for primary AF are lower with prolonged AF duration (persistent and long-standing persistent AF), increasing age, female sex, overweight, smoking, alcohol consumption, excessive exercise, hyperlipidaemia, obstructive sleep apnoea, hypertension, hyperglycaemia, impaired renal function, HFrEF, enlarged LA, diagnosis to ablation time, and early recurrence of AF after rhythm therapy (1, 48-50, 58, 59). Some of the risk factors were linked together to

create a risk stratification model for recurrence prediction, such as APPLE-, DR-FLASH-, and MB-LATER-scores (60). Growing literature confirms the role of atrial fibrosis as well, detailed in the next chapter.

1.2. ATRIAL FIBROSIS

1.2.1. *SIGNIFICANCE OF ATRIAL FIBROSIS*

Atrial fibrosis is a significant contributor to the complex pathomechanism of AF, thus, it is associated with AF recurrence after rhythm therapy (61). AF and atrial fibrosis together contribute to a vicious circle: while the arrhythmia itself can lead to “structural, architectural, contractile, or electrophysiological changes” in the atria; the fibrotic changes help in the manifestation of AF (62, 63). Fibroblast activation, inflammatory infiltration, and the development of atrial fibrosis cause local heterogeneity in the conduction system leading to a potential microreentrant arrhythmia (64, 65). The known risk factors of AF contribute to this atrial structural remodelling and consistent loss of atrial function (62, 66). Moreover, the increasing atrial pressure followed by atrial dilatation also plays an important role in the pathophysiology (67). Interestingly, those mechanisms are also observed in AF without any comorbidities. Kottkamp et al. suggested that the presence of fibrosis-driven atrial tissue damage cannot be solely explained by ageing, or underlying heart disease, or the AF burden itself, but AF is an element of the independent “arrhythmic manifestation” of the progressing fibrotic atrial cardiomyopathy (68). Histological examinations of atrial biopsy samples have proved that in severely remodelled atrial tissue and interstitial fibrosis are found both in persistent AF patients without concomitant diseases and in AF patients associated with underlying CV diseases. However, no interstitial fibrosis, minimal cardiomyocyte hypertrophy and myolitic damage was observed in controls (age-matched patients without known AF) (62, 69).

The nomenclature for atrial fibrosis also shows variability. Atrial fibrosis, atrial scar and atrial cardiomyopathy are often addressed as synonyms throughout the previously cited literature. Furthermore, depending on the imaging technology used to quantify fibrosis, it could be manifested as late gadolinium enhancement (LGE) or delayed enhancement (DE) by MRI, low voltage area by EAMS, and decreased atrial function, decreased compliance, or increased stiffness by echocardiography (70). All these conditions refer to the same remodelled, fibrotic atria.

In order to quantify atrial fibrosis, various methods have been developed to help the risk stratification of AF patients: cardiac imaging by DE-MRI, LA function by echocardiography, intracardiac electrogram analysis by electrophysiology procedure (EP) based on local conduction velocity, complex fractionated electrograms or voltage mapping (62). In the next chapter, I will present the role of DE-MRI and voltage mapping.

1.2.2. *QUANTIFICATION OF ATRIAL FIBROSIS*

1.2.2.1. **MRI and atrial fibrosis**

DE-MRI has become a well-validated technique for the diagnosis of LA fibrosis (70). During DE-MRI gadolinium contrast agent is administered, which accumulates for a longer time in the fibrotic tissue, causing delayed enhancement, and thereby the visualisation of the atrial fibrosis (71). It has been also validated by histological examinations based on surgical biopsy samples conducted by the research group of Marrouche (72). They presented the Utah classification in the DECAAF-study, where patients were divided into 4 stages regarding the percentage of fibrotic area of the total LA wall: stage 1 ($< 10\%$); stage 2 ($10\%-20\%$); stage 3 ($20\%-30\%$); and stage 4 ($\geq 30\%$). The degree of LA fibrosis has been independently associated with arrhythmia recurrence post-PVI ablation in other publications as well (72-75). The advantage of DE-MRI is the non-invasive approach and the automatic fibrotic area estimation. This method also strongly correlated with the low voltages on EAM and the decreased LA function assessed by echocardiographic speckle tracking (73, 76, 77).

However, the estimation of LA fibrosis by DE-MRI have not been widely used in routine clinical practice (70). Limitations of DE-MRI are the length of the procedure (about 45 minutes per patient), the financial burden and limited availability (78). Furthermore, the contraindication of contrast agent in severe renal dysfunction could cause a selection bias in the studies (78). Another downside of this method is the relatively poor spatial resolution in the thin LA wall, making it more difficult to perform good-quality images, leading to numerous exclusions due to tachyarrhythmia, irregular respiration, and high body mass index, generating also a potential selection bias (70, 72). Post-processing analysis is time-consuming (up to one hour per patient) and requires special training (79). Thus, the reproducibility of the results is difficult, causing several discussions on the overall validity of the method (70, 80-82).

1.2.2.2. Voltage mapping

Voltage mapping is an invasive method to assess the voltage of the myocardial surface with an EAMS during the EP procedure in order to detect low voltage area (LVA) associated with underlying fibrosis (62). The EAMS detect the location and orientation of the catheter's tip, as it moves real time in three dimensions around the endocardial tissue using magnetic field sensors and/or impedance ranging (83, 84). A mapping catheter can be a direct contact catheter collecting electrograms point-by-point, or a multi-electrode catheter. The mapping catheter collects multiple points simultaneously at each heart beat (QRS complex) with predefined beat acceptance criteria (e.g. cycle length stability and/or range, position/distance stability, QRS morphology/electrocardiogram stability, respiratory phase, speed of the catheter motion) (83, 85). The catheter's location and the simultaneously contact-based or noncontact-based collected local electrical data (electrogram, activation, timing, unipolar or bipolar voltage values) are stored by the EAMS (83, 84). Each point has location and electrical information associated with it. Bipolar endocardial voltage is calculated as a difference between two adjacent unipolar signals with the use of a differential amplifier or by post-processing (86). Afterwards, the EAMS do a surface reconstruction interpolating the collected data mostly between 3 points creating a color-coded voltage map. In general, LVAs are estimated based on the presence of ≥ 3 adjacent low-voltage points by rectified contact bipolar endocardial voltage measurement, that are < 3 mm apart from each other, and reported as a percentage area of the total mapped left atrium (85, 87-90). A high-density EAM (HD-EAM) presenting LVAs is shown in Figure 2.




Figure 2. HD-electro-anatomical map (CARTO 3® platform with a CONFIDENSE™ module) displaying the low voltage areas of the left atrium (red, yellow, green and blue areas) and normal voltage areas (purple) – postero-anterior view (image of our working group).

The extent of LA low voltage area often is assessed by visual estimation only (87, 91), which has been shown to overestimate the amount of dense scar ($< 0.2\text{mV}$) and underestimate the extent of diseased atrial tissue ($< 0.5\text{mV}$) areas (92). However, with the reported novel EAM software it is possible to quantify the LVA burden exactly, automatically, online or offline, in a relatively short time (86, 92). The further advantage of LA fibrosis estimation with voltage mapping is its high resolution with a spatial resolution within millimetres.

The disadvantage of EAM is the invasive method of LA fibrosis assessment, which prolongs the EP procedures depending on the catheter used, challenging anatomy, cardiac rhythm, the number of points collected, software settings, and the experience of the investigator (86, 93, 94). In order to overcome these limitations, algorithms of EAMS are helping the investigator to improve good catheter contact (e.g. tissue proximity indication filter and respiratory gating in EAMS, contact force sensing catheters, catheter tip direction) and annotation of complex intracardiac signals (e.g. far field, spacing artefact, noise, catheter orientation), and to correctly interpret the EAM (e.g. setting thresholds, merging the created map with pre-ablation CT or MRI images) (83). Furthermore, there is a significant diversity in the cut-off values determining the burden of LA LVA, ranging from 0.1-1.5mV, with 0.5mV being most commonly used term (85, 92, 95). The above

presented, sometimes subjective and investigator-biased methods can raise concerns regarding the accuracy of LA voltage information. Regarding the definition of severity, the most simplistic approach of classification is based on the presence or absence of the LVAs, while others use four different stages (i.e. none, mild, moderate and severe), some adopt the burdens presented in the DECAAF-study detailed one chapter earlier (87, 89, 96-98). There is no consensus on the cut-offs for defining the groups of fibrosis severity, used in the prediction of CA outcomes (86-88, 96).

Although AF is known to cause biatrial fibrosis, the literature has focused on the LA. As a result, scarce evidence is available on the fibrosis of the right atrium (RA). Akutsu et al. reported that AF provides symmetrical structural and electric alterations in both atria, and the biatrial remodelling independently affects the outcome of AF ablation (99).

1.2.3. *LOW VOLTAGE AREA AS TARGET FOR ABLATION*

The indication to target non-PV areas during ablation is restricted to special individualized cases, as its clear benefit has been still an unresolved issue (18-22). Various techniques are used for voltage-guided substrate modification: box isolation of the fibrotic area (BIFA), scar homogenization, adding extra ablation lines on the posterior wall, or around the mitral isthmus (86).

There are multiple studies underlining the LVA-guided ablation strategy's positive effect on success rates. Rolf et al. presented the first case, where substrate modification was done right after PVI, in case of $LVA < 0.5\text{mV}$ and inducible regular atrial tachycardia, resulting in a similar success rate compared to PVI-only group without LVA, and a better outcome compared to a historical PVI-only group with LVA (100). Kircher et al. reported a better outcome for patients undergoing LVA-targeted ablation (homogenization, linear lesion, or electrical isolation of LVA) vs PVI-only for paroxysmal and PVI plus box isolation (roof, posterior, and mitral isthmus line) for persistent AF (22). A review suggested a better outcome and a reduced occurrence of post-ablation atrial tachycardia for PVI plus LVA-targeted ablation compared to PVI plus conventional empirical wide ablation strategy. However, the definition of conventional empirical wide ablation was not well established (101). In the study of Yamaguchi et al., patients with LVA undergoing LVA-based substrate modification had fewer recurrence rates, than patients with LVA without additional ablation targets (102). Furthermore, Shreiber et al.

compared patients with no fibrotic atrial cardiomyopathy (FACM) (PVI-only ablation) to patients with and FACM stages I-IV (PVI with additional BIFA ablation strategy). According to their results, there was only a trend for better outcome in patients with no LVA. However, they also found that the extended total severe fibrosis area size ($< 0.5\text{mV}$) comes with an unfavourable impact on success rate (103).

1.3. THE PERI-ABLATION ROLE OF CARDIAC CT ANGIOGRAPHY

In 49%, pre-ablation cardiac CTA is used to tailor ablation, as a survey of the writing group members of HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of AF reported (5). Our EP Laboratory uses this imaging technique on a routine basis nearly for every AF patient, since among other findings, a variant left atrial anatomy may affect the ablation strategy. PV variants can be found in 29-62% leading to a high possibility of not being suitable for ablation with cryoballoon or with multielectrode radiofrequency catheters (104, 105). Atrial dimensions and alterations, such as the left atrial appendage size, the orientation of right superior PV, the ostium area of left inferior PV, the abutting left atrial appendage and left superior vein, or the presence of posterior LA adipose tissue may also influence the success of PVI (105-109). On the other hand, Di Cori et al. reported, that pre-procedural cardiac CTA had no additional impact on success rates of ablation, but it increased statistically significant the cumulative radiological exposure (110), which is the main reason why pre-ablation cardiac CTA has still not been a mandatory workup before ablation (5). However, if cardiac CTA is well-timed, it can be also used for pre-ablation LA thrombus exclusion replacing the invasive TOE (5, 111).

Ling et al. reported for the first time that the image attenuation ratio derived from contrast-enhanced multidetector CT is associated with LA bipolar voltage. Based on their results, cardiac CT could be a useful alternative tool for LA fibrosis diagnosis (112).

An additional benefit of pre-ablation cardiac CTA could be the newly diagnosed incidental alterations, which would alter the patient's management and may also have a potential lifesaving effect (113). In a recent study of ours, 42% (820/1,952) of the patients had at least one incidental extracardiac finding, of which half of the cases were determined as clinically significant (114). The most common findings were pulmonary changes; lung nodules over 6 mm were detected in 3% (62/1,952) of the cases. Other

investigations reported 23-72% extracardiac findings and 16-33% clinically relevant cases (115-117).

If a more detailed analysis was performed during the pre-ablation cardiac CTA, the coronary artery status could be also revealed (coronary CTA). According to several publications, at least 10%, or in some cases even 70% of patients with AF had newly diagnosed coronary artery disease (CAD) (Figure 3.) (118-121). Since symptoms suggesting ischemic heart disease, such as chest pain could be observed in AF patients without CAD also, predicting CAD in AF patients is often challenging (122). An incidental obstructive CAD ($\geq 50\%$ luminal stenosis) or an advanced coronary artery calcium (CAC) require preventive treatment to decrease potential ischaemic events. It may also cause the reclassification of the most commonly used thrombotic risk stratification, the CHA₂DS₂-VASc score, which could alter the anticoagulant strategy of AF patients (120, 123). A subclinical CAD may affect the success of AF ablation (124), however, some publications reported no significant impact (125, 126).




Figure 3. Obstructive coronary artery disease – significant stenosis on LAD (left anterior descending artery) diagnosed by coronary CTA (Image of our working group)

The complication rate of CA is approximately between 4-14%, of which 2-3% are potentially life-threatening (1, 127). CTA can also be a good tool to diagnose concealed complications, such as atrio-oesophageal fistula and pulmonary vein stenosis. It is also used to reveal post-ablation stroke, or could be a supplemental element to ultrasound for any vascular complications (1).

2. OBJECTIVES

2.1. ATRIAL LOW VOLTAGE AREA

We aimed to assess the LA LVA on HD-EAM by a novel software package which allows its automated quantification in our prospectively involved consecutive patients undergoing their first PVI for AF. We developed a graded classification system of the left atrial LVA using two different cut-offs: $\leq 0.2\text{mV}$ (equals Dense Left Atrial Scar), and $\leq 0.5\text{mV}$ (equals Diseased Left Atrial Tissue). We studied pre-procedural variables to set up risk factors for atrial fibrosis (128).

Our goal was also to assess the relationship between RA and LA LVA using HD-EAM in patients with AF. We used the previously determined LVA burden (Diseased Atrial Tissue) in both atria and we tried to identify the predisposing factors for higher RA Diseased Tissue burden (129).

Next we intended to analyse the predictive value of the Dublin Classification (Diseased LA Tissue burden) of recurrent AF in patients undergoing their first PVI (130).

2.2. CORONARY ARTERY DISEASE

We aimed was to assess the incidence of obstructive CAD by pre-ablation coronary CTA in consecutive patients with AF ablation. Our goal was also to study the relationship between traditional CV risk factors, the presence of chest pain and newly diagnosed obstructive CAD (Herczeg et al., 2022, under review).

3. METHODS

3.1. QUANTIFICATION AND RISK FACTORS OF ATRIAL LOW VOLTAGE AREA AND ITS RELATIONSHIP WITH THE SUCCESS RATE OF AF ABLATION

3.1.1. *STUDY POPULATION*

In our observational, prospective, single-centre study one hundred consecutive patients with either paroxysmal or persistent AF were included who underwent PVI in 2017 in the Mater Private Hospital, Dublin, Ireland. Exclusion criteria were: AF or atrial tachycardia during HD-EAM, and previous LA ablation (128). In a subset of the patient population, biatrial HD-EAM was obtained before PVI, which served as a basis for our second observational study, where we described the role of the RA. Patients with prior RA ablation or with persistent RA arrhythmia during mapping were excluded (129). In the follow-up study we extended our study population and included the follow-up data to analyse the factors associated with the recurrence of AF. Patients were excluded from the data analysis who received any additional non-PVI LA site ablation (130).

All the patients gave their prior written informed consent. The study protocols were reviewed and approved by the Clinical Research Ethics Committee of the Mater Misericordiae University Hospital and were in accordance with the declarations of Helsinki.

3.1.2. *ABLATION AND HD ELECTRO-ANATOMICAL MAPPING*

The procedures were performed under general anaesthesia in line with the up-to-date routine clinical AF ablation protocols (5). Briefly, a circular multipolar catheter with 20 electrodes (Lasso, Biosense Webster Inc., Irvine, California, USA; adjustable 15- to 25-mm circumference; 1–2mm inter-electrode spacing) was guided transseptal to the LA. Afterwards, an HD-EAM was performed in sinus rhythm (or in case of bradycardia with 600-ms cycle length coronary sinus pacing) by using the CARTO 3® platform with a CONFIDENSE™ module (Biosense Webster Inc., Irvine, California, USA) with filters enabled to ensure a good contact and catheter stability. Mapping was guided by electrogram characteristics, CARTO 3® imaging, tissue proximity indication filter, and fluoroscopy to map the whole atrium excluding noise and pacing spike artefacts. In case of anatomical challenges, the ablation catheter (ThermoCool SmartTouch™ 8Fr, Biosense Webster Inc., Irvine, California, USA) was also used for mapping to add more

details. The number of points created, the time of mapping and the volume of mapped LA were also recorded. After merging the created EAM with the pre-procedural cardiac CTA images, PVI with bilateral wide antral circumferential ablation method was performed with the ablation catheter. If typical atrial flutter was documented beforehand, an additional cavotricuspid isthmus line ablation was performed at the discretion of the investigator. LVAs were not a target during ablation. Moreover, if an additional LA non-PV site was ablated, those patients were excluded from the follow-up study, to maintain a homogenous group for data analysis (128).

In the study examining biatrial LVAs, the ablation method remained the same. However, the mapping strategy was extended to include the RA as well. Firstly, LA mapping and PVI were performed and then the circular multipolar mapping catheter was pulled back to the RA to acquire an HD-EAM (129).

3.1.3. *VOLTAGE MAP OFFLINE ANALYSIS*

In every case the LA appendage, the PVs, and the mitral annulus were manually excluded from the voltage map. Analyses of the HD-EAMs were made offline with a novel, automatic voltage histogram analysis (VHA) tool of the CARTO 3® platform. This tool uses the triangulated mesh of the created HD-EAM. It averages the voltages of the three closest points, to calculate the voltage of the created small triangular area. After setting the voltage ranges to ≤ 0.2 mV and ≤ 0.5 mV (as they are the most often used cut-off values), we calculated the percentage surface area of LA LVAs falling within the pre-set ranges. Areas with voltage ≤ 0.2 mV were defined as “Dense LA Scar”, while areas with voltage ≤ 0.5 mV as “Diseased LA Tissue”. Next, quartiles were calculated to categorize patients by the extent (percentage) of Dense LA Scar (≤ 0.2 mV) and Diseased LA Tissue (≤ 0.5 mV) as well. The lowest percentage surface area quartile was categorized as “Class I”, while the highest percentage surface area quartile was categorized as “Class IV” (128). In our third study we named the classification by Diseased LA Tissue, as “Dublin Classification”, using the same burden as set in our first study, thus, inventing a novel classification for LVAs (130).

During the offline RA voltage map analysis, inferior and superior vena cava and the tricuspid annulus were excluded from the RA map. In our second study, the quartiles for Diseased LA Tissue (≤ 0.5 mV) and RA Tissue (≤ 0.5 mV) were created for each atrium:

Q1 as the lowest quartile, while Q4 as the highest quartile of Diseased LA/RA Tissue (129).

3.1.4. MEASUREMENT OF ATRIAL DIMENSIONS

Atrial volumes were determined by the CARTO 3[®] platform, based on the created fast anatomical maps during ablation.

In our second and third studies we extended the data of atrial dimensions with the measurements based on pre-ablation cardiac CTA. On cardiac CTA images the shortest longitudinal atrial diameter (L), atrial area on two- (A1) and four-chamber (A2) views were measured in end-systole using Carestream version 11 Software (Phillips Healthcare, Amsterdam, The Netherlands). LA volume and RA volume (LAV/RAV ml) were calculated afterwards, based on the area-length method equation ($8/3\pi \times [(A1) \times (A2)/L]$) (131-133). Indexed LAV (LAVI) and indexed RAV (RAVI) (ml/m²) were also reported as indexed to body surface area (BSA) (129).

3.1.5. FOLLOW-UP

Follow-up data were collected for our third publication. Patients with no complications were discharged a day after the procedure. All patients were given a proton pump inhibitor medication for 6 weeks and continued anticoagulation therapy for at least 6 weeks. Patients were scheduled for follow-up visits at 6 weeks, and 3, 6, and 12 months after the ablation. In case of any symptoms, an unscheduled visit was organised, otherwise, after 12 months, an annual visit was recommended. At every visit a 12 lead ECG and 24 hour Holter-ECG were obtained. Recurrence was defined as a documented episode of AF, LA tachycardia or LA flutter lasting for more than 30 seconds. Ablation was regarded as successful, if no recurrence has happened after the three months long blanking period.

AAD therapy was terminated after 3 months. At the discretion of the investigator, in some cases, regular AAD was continued, restarted or used as a *pill in the pocket* therapy. Therefore, two separate success-analyses defining different primary endpoints (success definitions) were presented on the same studied population. Firstly, in patients without AADs (*OFF AAD*), the documented recurrence or AAD administration after the blanking period (even without any documented arrhythmia) were the primary endpoints. The second analysis (*ON AAD*) determined the primary endpoint only in case of documented recurrence irrespective of AAD usage.

3.2. OBSTRUCTIVE CORONARY ARTERY DISEASE IN PATIENTS WITH AF

3.2.1. *STUDY POPULATION*

This was a retrospective, observational study. Inclusion criteria were: patients with a history of AF and ≥ 18 years old in whom coronary CTA was performed before AF ablation between 2013 and 2020 at the Heart and Vascular Centre of Semmelweis University, Budapest, Hungary. We excluded patients if a previous CAD was known (history of acute myocardial infarction and coronary revascularization, known CAD treated conservatively), or the coronary CTA image was non-diagnostic to assess the coronary artery luminal stenosis. If multiple coronary CTA examinations were performed for one patient, the first good-quality image was included in the study. Demographics, medical history, and symptoms were collected pre-procedurally from questionnaires and medical documentation. Two groups were identified based on whether the patients had reported any type of chest pain or had no chest pain. Afterwards, we analysed the relationship between the collected data and novel obstructive CAD diagnosed by coronary CTA.

All the patients gave their prior written informed consent. The study protocol was reviewed and approved by the Local Research Ethics Committee of the Semmelweis University (SE RKEB: 142/2019) and was in accordance with the Declarations of Helsinki.

3.2.2. *CORONARY CT ANGIOGRAPHY AND IMAGE ANALYSIS*

Coronary CTA examinations were performed on a 256-slice scanner (Brilliance iCT 256, Philips Healthcare, Best, The Netherlands) with a prospective ECG-triggered axial acquisition mode. Metoprolol was administered for heart rate control if needed. In case of a heart rate < 80 /min, mid-diastolic triggering was applied with 3-5% padding (73-83% of the R-R interval), if the heart rate was ≥ 80 /min, systolic triggering was chosen (35-45% of the R-R interval). CAC was also measured. Non-contrast datasets were remodelled with a slice thickness and increment of 2.5 mm, while coronary CTA datasets were remodelled with 0.8 mm slice thickness and increment of 0.4 mm.

Cardiologist experts and radiologist experts evaluated the cardiac CTA images. Coronary artery status was analysed with a semi-automated software (HeartBeat-CS, Philips IntelliSpace Portal, Philips Healthcare, Best, The Netherlands). Coronary artery stenosis

was classified into seven groups according to the percentage of the measured most severe luminal stenosis: normal (absence of stenosis), minimal (1-25% stenosis), mild (25-49% stenosis), moderate (50-69% stenosis), severe (70-99% stenosis), and occluded (100% stenosis). We defined obstructive CAD as a lesion with $\geq 50\%$ luminal stenosis (134). Additionally, the total CAC score (CACS) was presented as well.

3.3. STATISTICAL ANALYSIS

Categorical variables are reported as numbers and percentages and analysed with the Fisher's exact test, the Chi-square test, and/or the Chi-square test for trend, as appropriate. Continuous variables showed a non-Gaussian distribution by using the Shapiro-Wilk normality test, thus, they were presented as median with interquartile ranges. At some parts, continuous data were split into two groups by using the median value (e.g. LAV, LAVI, RAVI), or by clinically used burdens (e.g. age, body mass index (BMI), BSA, CHA₂DS₂-VASc score, left ventricular ejection fraction (LVEF)), afterwards calculations for categorical data were performed. Otherwise, non-parametric variables were compared by the Mann-Whitney U-test.

Correlation between continuous parameters was analysed by the Spearman's correlation. For multiple comparisons, the Kruskal-Wallis test was used. The success rate of ablation was analysed by the Kaplan-Meier survival test, and compared by the log-rank test. To define the predictors of recurrence, we used the univariate Cox regression analysis. Uni- and multivariate analyses were performed by binary logistic regression using the entry method to study the association between Diseased LA Tissue Classes, obstructive CAD, traditional CV risk factors, and chest pain.

Statistical analysis was conducted with Prism (Version 6.01, GraphPad Software Inc., La Jolla, California, USA), and IBM SPSS Statistics (Version 25, IBM Corp., Armonk, New York, USA) software. A two-tailed $p < 0.05$ was considered statistically significant in every case.

4. RESULTS

4.1. QUANTIFICATION AND RISK FACTORS OF ATRIAL LOW VOLTAGE AREA AND ITS RELATIONSHIP WITH THE SUCCESS RATE OF AF ABLATION

4.1.1. QUANTITATIVE ASSESSMENT OF LEFT ATRIAL LOW VOLTAGE AREA

4.1.1.1. Patient demographics and distribution of left atrial low voltage area

One hundred patients were involved in our study, 27/100 (27%) were female, the median age was 64 [56-72] years. Persistent AF was present in 39/100 (39%) of the cases. Hypertension being the most common comorbidity was reported in 43/100 (43%) of the population. There were 45/100 (45%) patients scoring ≥ 2 CHA₂DS₂-VASc points. Median LAV was 144 [123-175] ml. A median of 1,049 [690-1,405] points were taken per voltage map in a median of 10 [8-15] minutes. A detailed description is shown in Table 1.

Table 1. Baseline patient characteristics (128).

Baseline and procedural characteristics (n=100)	
Female sex	27 (27%)
Age (years)	64 [56-72]
Persistent AF	39 (39%)
CHA ₂ DS ₂ -VASc score ≥ 2	45 (45%)
Congestive Heart Failure	9 (9%)
Hypertension	43 (43%)
Diabetes	1 (1%)
Prior Stroke or TIA	5 (5%)
Vascular Disease	16 (16%)
Coronary Artery Disease	9 (9%)
Underlying Heart Disease	16 (16%)
Prior CTI Ablation	8 (8%)
Left Atrial Volume (ml)	144 [123-175]
Number of Mapped Points	1049 [690-1,405]
Time spent creating HD-EAM (min)	10 [8-15]
Dense LA Scar (%)	3.5 [0.8-7.8]
Diseased LA Tissue (%)	17.8 [8.9-30.5]

(AF = atrial fibrillation, TIA = transient ischemic attack, CTI = cavotricuspid isthmus, HD-EAM = high-density electro-anatomical map, LA = left atrium)

We created quartiles for Dense LA Scar (≤ 0.2 mV) and Diseased LA Tissue (≤ 0.5 mV), as shown in Table 2. Figure 4. presents examples of HD-EAM from each class of Diseased LA Tissue.

Table 2. Thresholds for quartiles I-IV for classification of Dense Left Atrial (LA) Scar and Diseased LA Tissue. (128)

Classification by the extent of Dense LA Scar ($\leq 0.2\text{mV}$)		Classification by the extent of Diseased LA Tissue ($\leq 0.5\text{mV}$) (later named Dublin Classification)	
Class I	< 1%	Class I	< 9%
Class II	1-3%	Class II	9-18%
Class III	3.1-8%	Class III	18.1-31%
Class IV	> 8%	Class IV	> 31%

(LA = left atrium)




Figure 4. Anteroposterior view and Voltage Histogram Analysis of left atrial voltage maps: Class I-IV of Diseased Left Atrial Tissue burden (128).

4.1.1.2. Relationship of Diseased LA Tissue burden and patient characteristics

Trend analysis showed that the prevalence rate of female sex ($p=0.003$), age ≥ 65 years ($p<0.0001$), persistent AF ($p=0.004$), and CHA₂DS₂-VASc score ≥ 2 ($p<0.0001$) increased with every increment in Diseased LA Tissue from Class I to IV (Figure 5.)




Figure 5. Relationship between Diseased LA Tissue Classes and [a] sex category, [b] age, [c] type of AF and [d] CHA₂DS₂-VASc score (Chi-square test for trend) (128).

Similar results were reported with the Mann-Whitney U-test, where a significantly higher median Diseased LA Tissue burden was found in patients who were female (28% vs 16%, $p=0.001$), ≥ 65 years old (30% vs 13%, $p<0.0001$), had persistent AF (24% vs 14%, $p=0.002$), and those with a CHA₂DS₂-VASc ≥ 2 (26% vs 13%, $p<0.0001$) (Table 3.).

Table 3. Relationship between baseline characteristics and median percentage of Diseased LA Tissue burden assessed by the Mann-Whitney U-test (128).

	<u>Parameter present</u>		<u>Parameter absent</u>		p
	Number of patients	Diseased LA Tissue burden median %	Number of patients	Diseased LA Tissue burden median %	
Female sex	27	29	73	16	0.001
Age \geq 65 years	45	30	55	13	< 0.0001
Persistent AF	39	24	61	14	0.002
CHA ₂ DS ₂ -VASc \geq 2	45	26	55	13	< 0.0001
Congestive Heart Failure	9	28	91	17	0.42
Hypertension	43	21	57	15	0.11
Diabetes	1	14	99	18	N/A
Previous TIA / Stroke	5	26	95	17	0.20
Vascular Disease	16	20	84	18	0.67
Coronary Artery Disease	9	23	91	18	0.52
Underlying Heart Disease	16	21	84	17	0.81
Prior CTI ablation	8	32	92	17	0.21
LAV \geq 144ml	50	19	50	16	0.53

(AF = atrial fibrillation, TIA = transient ischemic attack, CTI = cavotricuspid isthmus, LA = left atrium, LAV = left atrial volume)

Furthermore, Diseased LA Tissue Classes I-III and Diseased LA Tissue Class IV were compared (Table 4). Patients with Diseased LA Tissue Class IV were more likely observed among patients \geq 65 years old (OR=11.16, CI 95%: 3.45-36.11, $p<0.0001$), female (OR=3.69, CI 95%: 1.40-9.72, $p=0.009$), ones with persistent AF (OR=3.19, CI 95%: 1.12-8.13, $p=0.01$), and among patients having CHA₂DS₂-VASc score \geq 2 (OR=4.57, CI 95%: 1.69-12.33, $p=0.002$) compared to Diseased LA Tissue Classes I-III. Multivariate analysis proved that only age \geq 65 years (OR=4.70, CI 95%: 1.50-14.71, $p=0.008$) and persistent AF (OR=10.50, CI 95%: 2.93-37.63, $p<0.0001$) were independent risk factors for the Diseased LA Tissue Class IV.

Table 4. Comparison of Diseased LA Tissue Class IV vs Diseased LA Tissue Classes I-III regarding baseline characteristics by Fisher's exact test (128).

	Class IV (n=25)	Class I-III (n=75)	p	OR	CI 95% of OR
Female sex	12	15	0.009	3.69	1.40-9.72
Age \geq 65 years	21	24	<0.0001	11.16	3.45-36.11
Persistent AF	15	24	0.01	3.19	1.25-8.13
CHA ₂ DS ₂ -VASc \geq 2	18	27	0.002	4.57	1.69-12.33
Congestive Heart Failure	2	7	1.00	0.84	0.16-4.36
Hypertension	12	31	0.64	0.76	0.31-1.99
Diabetes	0	1	N/A	N/A	N/A
Prior Stroke / TIA	2	3	0.59	0.48	0.08-3.05
Vascular Disease	3	13	0.75	1.54	0.40-5.91
Coronary Artery Disease	1	8	0.44	2.87	0.34-24.13
Underlying Heart Disease	2	14	0.34	2.64	0.56-12.53
Prior CTI ablation	4	4	0.10	0.30	0.07-1.29
LAV \geq 144ml	16	34	0.16	2.12	0.77-6.20

(AF = atrial fibrillation, TIA = transient ischemic attack, CTI = cavotricuspid isthmus, LA = left atrium, LAV = left atrial volume)

4.1.2. RIGHT ATRIAL DISEASED TISSUE BURDEN IN THE PREDICTION OF LEFT ATRIAL DISEASED TISSUE BURDEN

4.1.2.1. Patient and procedure characteristics

A total of 36 patients were included in this study with a median age of 69 [58-75] years, who were mainly male (27/36, (75%)), and had persistent AF in 21/36 (58%) of the cases (Table 5). The studied population had a CHA₂DS₂-VASc score of two or higher in 23/36 (64%), hypertension in 15/36 (42%) and coronary artery disease in 8/36 (22%). Nine patients had structural heart disease (7 with ischemic heart disease, 1 with non-ischemic dilated cardiomyopathy and 1 with prior aortic valve replacement and coronary bypass graft surgery). The median of the LVEF was within the normal range (56% [52-61%]). Left atrial and right atrial indexed volumes were mildly elevated based on the CTA images (59 [50-78] ml/m², and 53 [37-66] ml/m², respectively).

During the procedure, nearly one thousand homogenous points (987 [680-1,165] LA; 897 [658-1,153] RA) were collected for LA and RA in 8 [6-9] and 7 [6-8] minutes of procedure times, respectively (Table 5). The median Diseased Tissue burden (\leq 0.5 mV) assessed by the VHA tool was 19% [13-53%] for LA and 24% [14-34%] for RA.

Table 5. Baseline patient characteristics (129).

Baseline characteristics (n=36)		
Female sex	9	(25%)
Median age (years)	69	[58-75]
BMI (kg/m ²)	27	[26-29]
BSA (m ²)	2.0	[1.8-2.1]
Persistent AF	21	(58%)
CHA ₂ DS ₂ -VASc ≥ 2	23	(64%)
LVEF (%)	56	[52-61]
Hypertension	15	(42%)
Diabetes	4	(11%)
Prior Stroke / TIA	3	(8%)
Vascular Disease	5	(14%)
Coronary Artery Disease	8	(22%)
Structural Heart Disease	9	(25%)
LAVI _(CTA) (ml/m ²)	59	[50-78]
RAVI _(CTA) (ml/m ²)	53	[37-66]
Number of LA points	987	[680-1,165]
Number of RA points	897	[658-1,153]
LA mapping time (min)	8	[6-9]
RA mapping time (min)	7	[6-8]
Diseased LA Tissue (%)	19	[13-53]
Diseased RA Tissue (%)	24	[14-34]
LAVI _(HD-EAM) (ml/m ²)	78	[60-84]
RAVI _(HD-EAM) (ml/m ²)	87	[71-100]

(BMI = body mass index, BSA = body surface area, AF = atrial fibrillation, LVEF = left ventricular ejection fraction, TIA = transient ischemic attack, LAVI/RAVI = left/right atrial volume index, CTA = CT-angiogram, HD-EAM = high-density electro-anatomical map)

4.1.2.2. Relationship of Diseased RA Tissue and baseline characteristics

We determined the relationship between the baseline characteristics and the percentage of diseased RA tissue burden. Patients with a CHA₂DS₂-VASc score ≥ 2 (p=0.03), larger LAVI measured on CTA (p=0.02) and on 3D EAM (p=0.006), larger RAVI measured on 3D EAM (p=0.002) had significantly higher RA Diseased Tissue burden (Table 6.).

Table 6. Relationship between baseline characteristics and percentage of Diseased RA Tissue burden calculated by Mann-Whitney U Test (4).

	<u>Parameter present</u>		<u>Parameter absent</u>		p
	Number of patients	Diseased RA Tissue burden median %	Number of patients	Diseased RA Tissue burden median %	
Female sex	9	30	27	21	0.17
Age ≥ 65 years	20	30	16	20	0.12
BMI ≥ 30 kg/m ²	6	27	30	23	0.78
BSA ≥ 2 m ²	16	22	20	24	0.70
Persistent AF	21	28	15	19	0.07
CHA ₂ DS ₂ -VASc ≥ 2	23	30	13	15	0.03
LVEF $< 50\%$	4	26	32	24	0.98
Hypertension	15	21	21	28	0.96
Diabetes	4	27	32	21	0.29
Previous stroke / TIA	3	24	33	24	0.74
Vascular Disease	5	30	31	21	0.34
Coronary Artery Disease	8	27	28	23	0.53
LAVI _(CTA) ≥ 59 ml/m ²	17	30	18	15	0.02
RAVI _(CTA) ≥ 53 ml/m ²	17	30	18	20	0.10
LAVI _(HD-EAM) ≥ 78 ml/m ²	18	31	18	16	0.006
RAVI _(HD-EAM) ≥ 87 ml/m ²	18	31	18	15	0.002
LA-Q4	9	38	27	19	0.0007

(BMI = body mass index, BSA = body surface area, AF = atrial fibrillation, LVEF = left ventricular ejection fraction, TIA = transient ischemic attack, LA/RA = left/right atrium, LAVI/RAVI = left/right atrial volume index, CTA = CT-angiography, HD-EAM = high-density electro-anatomical map)

4.1.2.3. Correlation between Diseased RA and LA Tissue

We examined the correlation of LA and RA low voltage area percentages, and found a statistically significant correlation (≤ 0.1 mV: $p < 0.0001$, $R = 0.5760$; ≤ 0.2 mV: $p < 0.0001$, $R = 0.6250$; ≤ 0.3 mV: $p < 0.0001$, $R = 0.6120$; ≤ 0.4 mV: $p < 0.0001$, $R = 0.6660$; ≤ 0.5 mV: $p < 0.0001$, $R = 0.6461$, Spearman's correlation).

We also determined the relationship of the extent of Diseased RA Tissue and Diseased LA Tissue. Patients with higher Diseased LA Tissue quartiles had higher percentage of Diseased RA Tissue ($p = 0.003$), while patients with higher Diseased RA Tissue quartiles had a higher percentage of Diseased LA Tissue area percentage ($p = 0.001$) according to Kruskal-Wallis test, as presented in Figure 6. Also, patients in RA-Q4 more frequently belonged to LA-Q4 (OR=7.1, CI 95%: 1.3-38.9, $p = 0.01$, Chi-square test).




Figure 6. Comparison of Diseased Left Atrial (LA) and Right Atrial (RA) Tissue burden (Kruskal-Wallis test, error bars – median with interquartile ranges; Q – quartiles) (129)

4.1.3. PREDICTIVE VALUE OF LEFT ATRIAL LOW VOLTAGE AREA FOR THE OUTCOME OF ABLATION

4.1.3.1. Patient and procedure characteristics

In our third study, 109 dominantly male (83/109 (76%)) patients were included with a median age of 62 [55-70] years (Table 6.). Almost one third (34/109 (31%)) of the patients had persistent AF. Hypertension (39/109, 36%), vascular disease (16/109, 15%) and underlying heart disease (16/109, 15%) were the most frequent comorbidities. Seven per cent (8/109) of the patients had LVEF < 50%.

Table 6. Baseline and procedural characteristics (130).

Parameters (n=109)	
Female sex	26 (24%)
Median age (years)	62 [55-70]
Median BMI (kg/m ²)	28 [26-31]
Persistent AF	34 (31%)
CHA ₂ DS ₂ -VASc score ≥ 2	41 (38%)
LVEF < 50%	8 (7%)
Hypertension	39 (36%)
Diabetes	0 (0%)
Prior stroke / TIA	5 (5%)
Vascular Disease	16 (15%)
Coronary Artery Disease	10 (9%)
Underlying Heart Disease	16 (15%)
Prior CTI ablation	8 (7%)
Median LAV _(CTA) (ml)	142 [124-169]
Median No. of Mapped LA points	958 [658-1,257]
Mapping time (min)	10 [8-14]
Dense LA Scar (≤ 0.2mV) (%)	2.49 [0.54-7.17]
Diseased LA Tissue (≤ 0.5mV) (%)	15.85 [6.94-28.41]

(AF – atrial fibrillation, BMI – body mass index, CTA – CT angiography, CTI – cavotricuspid isthmus, LAV – left atrium (volume), LVEF – left ventricular ejection fraction, TIA – transient ischaemic attack)

During the procedure, median 958 [658-1,257] points were collected while mapping the LA in the median of 10 [8-14] minutes. All patients were classified: (1) by the extent of Dense LA Scar ($\leq 0.2\text{mV}$) and (2) by the extent of Diseased LA Tissue ($\leq 0.5\text{mV}$) defined as Dublin Classes I-IV (Table 7.), based on the classification range set in our previous publication (Table 2.) (128).

Table 7. Distribution of the study population in the Dense LA Scar and Dublin Classes (130).

Classification by the extent of Dense LA Scar ($\leq 0.2\text{mV}$)		No. patients (n=109)	Classification by the extent of Diseased LA Tissue ($\leq 0.5\text{mV}$) (Dublin Classification)		No. patients (n=109)
Class I	< 1%	36 (33%)	Dublin Class I	< 9%	36 (33%)
Class II	1-3%	21 (19%)	Dublin Class II	9-18%	25 (29%)
Class III	3.1-8%	29 (27%)	Dublin Class III	18.1-31%	27 (25%)
Class IV	> 8%	23 (21%)	Dublin Class IV	> 31%	21 (19%)

(LA – left atrium)

The acute success of the PVI, demonstrated by the entrance block to the veins, was achieved in all cases. Five (5/109, 5%) major complications were recorded (3 pericardial effusion requiring pericardial drainage, 1 severe pericarditis, and 1 right phrenic nerve palsy) all being un-related to the mapping process and the VHA, and resolved without sequel.

4.1.3.2. Follow-up results and overall success rates

The median duration of the follow-up period was 632 [469-760] days. 30/109 (28%) patients had palpitations during the blanking period with or without ECG documentation. After the blanking period 23/109 (21%) patients had taken AADs. We detected 33/109 (30%) recurrences with ON AAD analysis, and 35/109 (32%) with OFF AAD analysis. Out of the 25/75 (33%) patients with paroxysmal AF who had a recurrence, 18/25 (72%) patients continued to have paroxysmal AF and 5/25 (20%) progressed to a persistent stage. Two out of twenty-five (8%) patients experienced no recurrence, however they stayed on AADs up to 4 months after PVI, thus, had reached the set endpoint of the OFF AAD analysis. Out of the 10/34 (29%) patients who had persistent AF before ablation and experienced a recurrence, 8/10 (80%) developed persistent AF and in 2/10 cases (20%) we observed an improvement to a paroxysmal type of AF post-ablation. Altogether 12/109 (11%) patients underwent electrical cardioversion and 24/109 (22%) patients

underwent repeated ablation. The overall success rate was 78% and 67% ON AAD, and 74% and 67% OFF AAD at 1- and 2-years follow-up, respectively (Figure 7.).




Figure 7. The overall success of first pulmonary vein isolation for atrial fibrillation, ON AAD (left) and OFF AAD (right) analysis, Kaplan-Meier curve (130).

Firstly, the success rates of CA in the different Dense LA Scar Classes (I-IV) were compared, but no statistically significant difference was found ($p=0.20$ ON AAD; $p=0.38$ OFF AAD; log-rank test). However, the separation of the survival curves showed a tendency to lower success rates in Class IV. Therefore, Classes I-III were grouped together and compared with Class IV. Although, there was a tendency, we did not find a significant difference in the success rates between Dense LA Scar Classes I-III vs Class IV patients ($p=0.07$ ON AAD; $p=0.12$ OFF AAD; log-rank test, Figure 8.).




Figure 8. Success rates of patients with Class IV vs Classes I-III Dense LA Scar, ON AAD (left) and OFF AAD (right) analysis, log-rank test (130).

In the Diseased LA Tissue burden analysis, there was a statistically significant separation of the four survival curves; and the Dublin Class IV showed the lowest success rate ($p=0.01$ ON AAD; $p=0.03$ OFF AAD; log-rank test). Similarly, Dublin Classes I-III were grouped together and compared with Dublin Class IV. Patients with Dublin Class IV had a significantly lower success rate, than patients with Dublin Class I-III, irrespective of AAD use ($p=0.004$, ON AAD; $p=0.008$, OFF AAD; log-rank test; Figure 9.).




Figure 9. Success rates of patients with Dublin Class IV vs Dublin Classes I-III, ON AAD (left) and OFF AAD (right) analysis, log-rank test (130).

4.1.3.3. Predictors of recurrence

Next, we determined the predictors of recurrence with both ON AAD and OFF AAD analyses (Table 8.). Among the various clinical and procedural parameters, only two significant predictors were found with univariate Cox-regression analysis: the presence of arrhythmia in the blanking period (OR=3.14, CI 95%: 1.55-6.36, $p=0.001$ for ON AAD; OR=3.28, CI 95%: 1.65-6.52, $p=0.001$ for OFF AAD) and Dublin Class IV (OR=2.51, CI 95%: 1.22-5.14, $p=0.01$ for ON AAD; OR=2.27, CI 95%: 1.12-4.61, $p=0.02$ for OFF AAD, Table 8.).

Table 8. Univariate Cox-regression test for predictors of recurrence (separate ON AAD and OFF AAD analyses) (130).

Parameters	n (%)	ON AAD Analysis			OFF AAD Analysis		
		p	OR	CI (95%)	p	OR	CI (95%)
Female sex	26 (24%)	0.87	0.94	0.43-2.03	0.96	1.01	0.47-2.17
BMI > 30 kg/m ²	25 (23%)	0.73	1.15	0.51-2.55	0.35	1.41	0.67-2.98
Age ≥ 65 years	41 (38%)	0.28	1.45	0.73-2.90	0.47	1.27	0.65-2.50
Persistent AF	34 (31%)	0.90	0.95	0.45-2.01	0.62	0.83	0.39-1.74
CHA ₂ DS ₂ -VASc ≥ 2	41 (38%)	0.32	1.40	0.70-2.80	0.53	1.23	0.63-2.41
LVEF < 50%	8 (7%)	0.12	2.28	0.79-6.57	0.25	1.84	0.64-5.27
Hypertension	39 (36%)	0.97	1.01	0.50-2.04	0.81	0.92	0.46-1.83
Diabetes	0 (0%)	-	-	-	-	-	-
Prior Stroke / TIA	5 (5%)	0.11	2.63	0.79-8.69	0.12	2.52	0.76-8.30
Vascular Disease	16 (15%)	0.22	0.47	0.14-1.59	0.17	0.43	0.13-1.45
Coronary Artery Disease	10 (9%)	0.74	0.81	0.23-2.79	0.61	0.73	0.32-2.48
Underlying Heart Disease	16 (15%)	0.70	1.19	0.48-2.94	0.92	1.04	0.42-2.55
LAV > 142 ml (CTA)	56 (51%)	0.27	1.49	0.73-3.05	0.27	1.47	0.73-2.93
Arrhythmia in blanking period	30 (28%)	0.001	3.14	1.55-6.36	0.001	3.28	1.65-6.52
Class IV	23 (21%)	0.10	1.81	0.87-3.77	0.17	1.64	0.80-3.37
Dublin Class IV	21 (19%)	0.01	2.51	1.22-5.14	0.02	2.27	1.12-4.61

(AAD – antiarrhythmic drug, AF – atrial fibrillation, BMI – body mass index, CTA – computed tomography angiography, LAV – left atrial volume, LVEF – left ventricular ejection fraction, TIA – transient ischaemic attack)

4.2. OBSTRUCTIVE CORONARY ARTERY DISEASE IN PATIENTS WITH AF

4.2.1. PATIENT CHARACTERISTICS

A total of 3,335 pre-ablation coronary CTA examinations have met inclusion criteria. Of those, 570 cases were excluded due to non-diagnostic images, and 169 patients due to previously known CAD. Additionally, 274 images were excluded, because of multiple coronary CTAs being performed. In those cases, only the first good-quality image was involved. Finally, 2,321 patients with paroxysmal and persistent AF were included in our study population (Figure 10.).




Figure 10. Illustration of our study population (CCTA – coronary CT angiography, CAD – coronary artery disease, Image of our working group).

The median age of the involved patients was 63 [54-69] years. The main characteristics are shown in Table 9. The population was rather overweight: the median body mass index was 29 [26-32] kg/m². Hypertension was present in 68% (1,580/2,321) of the patients, 35% (803/2,321) had dyslipidaemia, and 31% (724/2,321) had a history of smoking. 17% (401/2,321) of the patients reported having a positive family history of CV diseases. There were 404/2,321 (17%) patients who mentioned any chest pain before the coronary CTA without any known CAD.

Table 9. Characteristics of the studied population.

Parameters	n=2,321
Age (years)	63 [54-69]
Female sex	1,052 (45%)
BMI (kg/m ²)	29 [26-32]
Hypertension	1,580 (68%)
Diabetes	313 (14%)
Dyslipidaemia	803 (35%)
History of smoking	724 (31%)
Positive family history of CV disease	401 (17%)
Peripheral vascular disease	108 (5%)
Prior stroke / TIA	126 (5%)
Any chest pain	404 (17%)

(BMI – body mass index, CV – cardiovascular, TIA – transient ischaemic attack)

4.2.2. COMPARISON OF PATIENTS WITH AND WITHOUT ANY CHEST PAIN

Patients with and without any chest pain were compared (Table 10.) Patients with any chest pain were statistically significant older (65 [58-70] vs 63 [54-69] years, $p<0.001$), rather female (59% (238/404) vs 43% (814/1,917), $p<0.001$), presenting with hypertension (72% (292/404) vs 67% (1,288/1,917), $p=0.04$), peripheral vascular disease (8% (31/404) vs 4% (77/1,917), $p<0.001$), and reporting positive family history of CV disease (24% (98/404) vs 16% (303/1,917), $p<0.001$). Obstructive CAD ($\geq 50\%$ luminal stenosis revealed by the current coronary CTA) was in equal distribution in both groups (23% (91/404) vs 21% (397/1,917), $p=0.41$), respectively.

Table 10. Comparison of traditional CV risk factors of patients with and without any chest pain, Mann-Whitney U-test and Chi-square test.

Parameters	Any chest pain (n= 404)	Without chest pain (n=1,917)	p
Age (years) [#]	65 [58-70]	63 [54-69]	< 0.001
Female sex [□]	238 (59%)	814 (43%)	< 0.001
BMI (kg/m ²) [#]	29 [26-32]	29 [26-32]	0.67
Hypertension [□]	292 (72%)	1288 (67%)	0.04
Diabetes mellitus [□]	53 (13%)	260 (14%)	0.80
Dyslipidaemia [□]	145 (36%)	658 (34%)	0.53
History of smoking [□]	127 (32%)	597 (31%)	0.88
Positive family history for CV disease [□]	98 (24%)	303 (16%)	< 0.001
Peripheral vascular disease [□]	31 (8%)	77 (4%)	0.001
Prior stroke / TIA [□]	25 (6%)	101 (5%)	0.46
Obstructive CAD [□]	91 (23%)	397 (21%)	0.41

([□] Chi-square test; [#] Mann-Whitney U-test; BMI – body mass index, CV – cardiovascular, TIA – transient ischaemic attack, CAD – coronary artery disease)

Multivariable analysis was performed too; factors associated with any chest pain were age > 65 years (OR=1.30, 95% CI: 1.03-1.64, p=0.02) female sex (OR=1.84, 95% CI: 1.47-2.30, p<0.001), positive CV family history (OR=1.70, 95% CI: 1.30-2.22, p<0.001), and peripheral vascular disease (OR=1.74, 95% CI: 1.11-2.75, p=0.01). Obstructive CAD was not associated with symptoms of chest pain (OR=1.06, 95% CI: 0.80-1.39, p=0.69).

4.2.3. CORONARY ARTERY STATUS OF THE STUDIED POPULATION

The severity of stenosis was determined on all coronary artery segments. In 577/2,321 (25%) no stenosis, 573/2,321 (25%) minimal, 683/2,321 (30%) mild stenosis was found. Moderate stenosis was observed in 311/2,321 (13%) of the patients, and severe ones in 151/2,321 (7%). Occluded coronary arteries were diagnosed only in 1 per cent (26/2,321). In total, 488/2,321 (21%) patients were diagnosed with novel obstructive CAD (\geq 50% luminal stenosis). The total median CACS was 17.8 [0.0-168.6].

We determined different factors associated with prevalent obstructive CAD with uni- and multivariable tests (Table 11.). In multivariable analysis age > 65 years (OR=2.51, 95% CI: 2.02-3.13, p<0.001), male sex (OR=1.59, 95% CI: 1.28-1.98, p<0.001), hypertension (OR=1.40, 95% CI: 1.08-1.81, p=0.01), diabetes (OR=1.50, 95% CI: 1.13-1.99, p=0.006), dyslipidaemia (OR=1.33, 95% CI: 1.07-1.66, p=0.01), and history of smoking (OR=1.34, 95% CI: 1.07-1.68, p=0.01) were identified as statistically significant associated factors for obstructive CAD. Any chest pain reported was not associated statistically significant with obstructive CAD (OR=1.06, 95% CI: 0.81-1.40, p=0.67).

Table 11. Factors associated with prevalent obstructive CAD as determined by uni- and multivariable analysis, using logistic regression.

Parameters	Univariate OR (95% CI)	p	Multivariable OR (95% CI)	p
Age > 65 years	2.68 (2.19-3.30)	<0.001	2.51 (2.02-3.13)	<0.001
Female sex	0.78 (0.64-0.96)	0.01	0.63 (0.50-0.78)	<0.001
BMI >25 kg/m ²	1.14 (0.88-1.48)	0.32	1.00 (0.75-1.32)	0.99
Hypertension	1.97 (1.56-2.50)	<0.001	1.40 (1.08-1.81)	0.01
Diabetes	2.07 (1.59-2.68)	<0.001	1.50 (1.13-1.99)	0.00
Dyslipidaemia	1.67 (1.36-2.04)	<0.001	1.33 (1.07-1.66)	0.01
History of smoking	1.23 (1.00-1.52)	0.05	1.34 (1.07-1.68)	0.01
Positive family history for CV disease	1.11 (0.85-1.43)	0.44	1.10 (0.83-1.45)	0.51
Peripheral vascular disease	2.04 (1.34-3.05)	<0.001	1.40 (0.90-2.18)	0.13
Prior stroke / TIA	1.67 (1.12-2.46)	0.01	1.39 (0.92-2.12)	0.12
Any chest pain	1.11 (0.86-1.44)	0.41	1.06 (0.81-1.40)	0.67

(BMI – body mass index, CV – cardiovascular, TIA – transient ischaemic attack)

5. DISCUSSION

5.1. VOLTAGE MAPPING AND ITS ROLE IN PATIENTS WITH AF

5.1.1. *TECHNICAL VARIANCES OF VOLTAGE MAPPING*

The technique of voltage mapping has still not been a standardized method among AF patients undergoing CA (86). Multiple studies have reported results of maps created in AF and/or in sinus rhythm (SR) (86, 135, 136). It has been already known that during AF atrial voltages are lower and more variable than during SR, which makes difficult to compare the results with each other (137, 138). Since the majority of the centres perform the procedure in SR, we also created the HD-EAMs in stable SR, or – in case of bradycardia – under pacing from the coronary sinus catheter.

Further difficulties arise from the interpretation of the LVAs, the choice and proper usage of various tools (ablation catheters and/or multielectrode mapping catheters) for mapping, and the numbers of mapped points (mean 100-1024) (86). Few studies have suggested that multipolar catheters overestimate the voltage values as compared to the points created by point-by-point ablation catheters (93, 95). However, the number of points collected with the ablation catheters were minimal in those studies (229 ± 96 , and 252 ± 184 , respectively), which makes the reported results questionable. Since more voltage points collected imply a more detailed and reproducible maps (139), we created HD-EAMs by multipolar mapping catheters with a higher number of collected points (median 1049 [IQR 690-1405]), as compared to what was documented in previous studies (86, 88, 128, 140). Those studies included between 41-201 patients according to the review of Sim et al., thus our patient group's size was comparable with those (86).

Since the often used visual estimation overestimates the amount of dense scar and underestimates the extent of diseased atrial tissue areas, novel EAM software is needed to estimate the LA fibrosis more accurately (86, 92). We presented in our publications a novel user-friendly tool, which creates automated, rapid, detailed, and potentially reproducible measurements to accurately assess the per cent of LA fibrosis based on the percentage of surface area fulfilling the pre-set criteria. With a quick change of the voltage burden, physicians can report any voltage range of interest and calculate the surface area percentage of the left atrium falling within that range offline, or even in an online setting (128, 130).

There is no consensus on the voltage threshold for defining left atrial fibrosis/scar, which has varied between $\leq 0.05\text{mV}$ and $\leq 0.5\text{mV}$ in studies published (95, 112, 141, 142). Some investigators have used a higher threshold varying between $0.5\text{-}1.5\text{mV}$, which is probably not a true dense scar (103, 112). We chose to apply the most frequently used $\leq 0.5\text{mV}$ threshold to be able to set quartiles for the Dublin Classification, as Diseased LA Tissue is a more likely substrate for the perpetuation of AF than the dense very low voltage ($\leq 0.2\text{mV}$) scars (103, 141). Our outcome results confirmed this burden since Diseased LA Tissue ($\leq 0.5\text{mV}$) was associated with the success rate of the PVI, while the classes of Dense LA Scar ($\leq 0.2\text{mV}$) showed no significant separation regarding the success rates (130).

Reporting the severity of LA fibrosis has also not been well established. Clinicians can assess it based on the presence or absence of the LVAs, some use visually estimated different stages (i.e. none, mild, moderate and severe), others apply the thresholds reported in the DECAAF-study adopting the burdens from MRI measurements (87, 89, 96-98). We used a purely mathematical approach by defining the quartiles based on the first one hundred patients' analysis. Based on our observation, we created a new classification for Diseased LA Tissue, the Dublin Classification. There was a statistically significant separation of the four survival curves of Dublin Classes, and Dublin Class IV showed the lowest success rate. We presented that Dublin Class IV predicts the outcome of PVI (130).

5.1.2. *RISK FACTORS OF LOW VOLTAGE AREA*

Several studies have been searching for factors associated with the presence of LA LVA; demographic parameters, female sex, and advanced age were the most frequently reported ones (88, 89, 143-145). The presence of low voltage zones was also higher in patients with chronic kidney disease, diabetes, hypertension, and obstructive sleep apnoea syndrome (62, 146-149). Echocardiographic data, such as enlarged LA, diastolic dysfunction and reduced LVEF were also related to lower LA voltage rates (62, 89, 143-145, 150). LVA was also more frequently observed in patients with persistent AF as compared to paroxysmal ones (138, 144). Additionally, CACS was significantly higher in the group with the presence of LVA compared to the non-fibrotic LA group (147). The CAAP-AF and CHA₂DS₂-VASc scores, which include CAD, were also associated with low voltage zones (151).

Based on the previous findings, few scores were created or framed in order to predict LA fibrosis. D'Ambrosio et al. invented the ZAQ score to predict the presence and extent of LVA including the following factors: age, female sex, and LAVI measured by CT (152). Another score, the SPEED score was presented by Matsuda et al., as a useful tool to predict the prevalence of LVAs involving factors such as female sex, persistent type of AF, serum B-type natriuretic peptide (BNP) level, serum N-terminal prohormone BNP (NT-proBNP) level and diabetes (153). The APPLE-score (age, persistent AF, impaired renal function, enlarged LA diameter, LVEF < 50%) was originally used for PVI outcome prognosis, but it turned to be a good marker for LVA prediction before AF ablation as well (154). Furthermore, the CHA₂DS₂-VASc score designed for thromboembolic risk stratification showed a good correlation with LVAs (88). The DR-FLASH score developed to estimate AF recurrence after CA. It performs well for LVA prediction and includes similar factors as described previously: diabetes, renal dysfunction, persistent AF, prolonged LA diameter, age, female sex, and hypertension (155). In a recent publication by Kiedrowicz et al., several risk factors were analysed for LVA prediction in long-standing persistent AF patients, where CAAP-AF ≥ 7 , DR-FLASH ≥ 4 , and CHA₂DS₂-VASc score ≥ 3 predicted the presence of LVA (151). CAAP-AF score incorporates CAD, LA diameter, age, persistent AF, number of failed AADs, and female sex (156). The most recently published AF-SCORE (age ≥ 60 years, female sex, persistent AF) showed also a good correlation with the presence of fibrotic atrial cardiomyopathy ($> 5\text{cm}^2$, $< 0.5\text{mV}$) (157).

Moreover, some lifestyle parameters, such as the regular moderate alcohol consumption and obesity were also factors associated with lower LA voltage (143, 158, 159).

Our results were in line to that of the cited publications. Higher median Diseased LA Tissue burden was found in patients who were female (28% vs 16%, $p=0.001$), ≥ 65 years old (30% vs 13%, $p<0.0001$), had persistent AF (24% vs 14%, $p=0.002$) and those with a CHA₂DS₂-VASc score ≥ 2 (26% vs 13%, $p<0.0001$). According to the multivariate analysis, only age ≥ 65 years (OR=4.70, CI 95%: 1.50-14.71, $p=0.008$) and persistent AF (OR=10.50, CI 95%: 2.93-37.63, $p<0.0001$) were independent factors associated with Dublin Class IV (128).

5.1.3. *PREDICTIVE ROLE OF LOW VOLTAGE AREA*

One of the most important reasons to study LA LVA is its potential predictive role in determining PVI outcomes. A detailed voltage map allows physicians to have a more thorough discussion with the patient after the CA with regards to the degree of atrial cardiomyopathy present and the long-term likelihood of AF cure by ablation (128).

There have already been multiple studies showing the predictive capacity of LA LVA presence and/or burden. Wang et al. created LA LVA ($< 0.5\text{mV}$) map by a contact-force sensing ablation catheter (150-200 points collected) in 150 patients. The percentage of LVA of the total LA surface was calculated by Carto[®] software and categorized into four groups: none (0%), mild ($< 10\%$), moderate (10-20%) and severe ($> 20\%$). Patients with $> 10\%$ LVA had a significantly higher risk for AF recurrence (89). Next, Vlachos et al. involved 80 patients with a higher resolution of the maps (median 2485 points) and used the DECAAF-study's four categories. According to their results, $> 10\%$ of $< 0.4\text{mV}$ LVA was the only predictor for AF recurrence (85). Furthermore, Begg et al. revealed that a high proportion ($> 30\%$) of LVA ($< 0.5\text{mV}$, multipolar mapping catheter, at least 864 points) mapped in SR or AF also predicts the outcome of PVI (160). Moteleb et al. used 5% of LVA ($< 0.5\text{mV}$, multipolar mapping catheter, ≥ 100 points) as a burden to estimate the success of CA after 6 months long follow-up: LVA and AF burden were the only significant predictors of ablation success (161). On the other hand, there have been a few publications suggesting opposite opinions. In a recent study by Takahashi et al. involving 448 patients, no correlation was found between $> 5\%$ of LVA ($< 0.5\text{mV}$, multipolar catheters, SR, mean 1,271 points) and CA success rates. However, they performed LVA targeted ablation additionally, which makes these results slightly comparable to that of the previously reported mainly PVI-only ablation strategies not targeting LVAs (146).

According to our findings, there is a clear association between the extent of Diseased LA Tissue (Dublin Classification) and the success of PVI. Patients in Dublin Class IV ($> 31\%$ of $\leq 0.5\text{mV}$) have a significantly higher chance of recurrence. No such observation was made with the Dense LA Scar classification ($\leq 0.2\text{mV}$) in our cohort. Arrhythmia in the blanking period was also a risk factor for AF recurrence. No other conventional baseline clinical parameters predicted the success of AF ablation (130).

We decided to present outcomes based on OFF AAD and ON AAD; for the results to be more comparable to what physicians experience in a clinical setting. In our studied population, the one- and two-year success rates were 57% and 45% for Dublin Class IV vs 78% and 73% for Dublin Classes I-III OFF AAD, while 57% and 45% for Dublin Class IV vs 83% and 73% for Dublin Classes I-III with the ON AAD analysis, respectively. These results indicate that the use of AAD did not relevantly affect the PVI outcome at 2 years. Parallel the literature data, our results on PVI success were within the previously reported ranges: 72-93% at one year with low, and 28-75% at one year with high LVA burden (85, 87-89, 96).

Our results may help to manage AF patients after ablation in a more personalized way. During a discussion about the degree of atrial cardiomyopathy and the long-term likelihood of AF cure, we could manage the patient's expectations too. In case of a high LVA burden an increased frequency of follow-up visits might be reasonable, or additional rhythm control therapies such as prolonged anti-arrhythmic therapy, or even further catheter ablation using different non-PV targets might be needed. On the other hand, a severe atrial fibrosis predicting an unsuccessful long-term rhythm control strategy, may facilitate a reduction in reablation procedures, resulting in a more conservative management with early frequency control strategy. However, further studies should confirm the clinical benefits of LA fibrosis imaging.

5.1.4. *BIATRIAL LOW VOLTAGE AREA*

The majority of publications have focused on LA fibrosis and only a few have demonstrated that RA is also affected in AF patients. Histological and molecular studies have suggested that the fibrotic changes at a cellular and subcellular level do happen in both atria and they are not limited to the LA (162, 163). Moteleb et al. measured the voltage of LA and RA as well. They reported fibrosis ($> 5\%$, $< 0.5\text{mV}$) in 6/29 (21%) cases in the LA, and only in 1/29 (4%) cases in the RA. The only patient with the RA LVA had a recurrence, however, of course, no further assumptions can be made based on this single case (161). Prabhu et al. performed biatrial mapping in 40 persistent AF patients with ablation catheters collecting a few hundreds of points. To determine the percentage of low voltage, they directly calculated the number of low voltage points related to the number of the total collected points, but not to the actual surface. They found that the LA and RA bipolar voltage showed a good correlation, and there was no

significant difference between their global voltage (LA $1.89 \pm 0.77\text{mV}$ vs RA $1.77 \pm 0.57\text{mV}$, $p = 0.57$) (164).

In our study we recorded biatrial voltages with multipolar catheters, creating HD-EAMs with a high number of collected points (LA median 987, RA median 897 points). Next, the previously described automated VHA tool allowed us the rapid LVA quantification in both atria. The presence of a high percentage of low voltage areas in the RA predicted the same in the LA and the percentage of Diseased Tissue burden correlated statistically significant between the two atria. The most important potential value of the automated RA LVA is that it can be used as a surrogate marker for the LA fibrosis, without the need for transseptal catheterization, for example in AF patients undergoing an EP study or RA ablation. Thus, the extent of the Diseased RA Tissue burden might provide useful information on the severity of AF, which would be an important clinical implication. However, further studies are still needed to confirm the predictive value of the automated RA LVA analysis on the success of AF ablation (129).

5.2. THE ROLE OF PRE-ABLATION CORONARY CT ANGIOGRAPHY IN AF PATIENTS

5.2.1. *RELATIONSHIP OF CHEST PAIN AND CORONARY ARTERY DISEASE IN AF PATIENTS*

There has been still a lot of uncertainties regarding the relationship between chest pain and AF. Rottlander et al. suggest that there might be only a weak association between AF patients hospitalized due to chest pain and relevant CAD (165). Furthermore, Brown et al. showed among 140 AF patients with chest pain syndromes that the patients had no increased risk for acute coronary syndrome as compared to a matched control group (11.4% vs 10.8%) (166). On the other hand, Graf et al. studied 79 patients reporting only typical chest pain (with no data available on cardiac rhythm) who had no stenosis on coronary arteries, but 65% had reduced coronary flow reserve (167). They suggested that clinical cardiac risk factor analysis may help the prediction of the individual probability of microvascular dysfunction (167).

In our study, chest pain was not associated with obstructive CAD. The incidence of obstructive CAD was similar in patients with and without any chest pain (23% vs 21%). Elderly, female patients, or patients suffering from peripheral vascular disease or hypertension, and subjects with positive family history for CV disease were more likely

to report chest pain. The difference between the associated factors for chest pain and obstructive CAD suggests that the reported chest pains are rather non-cardiac of origin or are related to AF. These findings underline the importance of coronary artery diagnostics in patients undergoing pre-ablation cardiac CTA, while patients without any symptoms could have hidden CAD as well.

5.2.2. *TECHNICAL VARIANCES OF CORONARY ARTERY DISEASE DIAGNOSTICS WITH CT*

In our practice, nearly every AF patient awaiting PVI undergoes pre-ablation cardiac CTA or MRI examination to gather information on atrial anatomy, possible cardiac thrombus or any accidental finding affecting the management of the patient.

Technical differences and variable definition of CAD make the comparison of literature data more complicated. Some use CACS detected on cardiac CT images without angiography. CAC was visually detected at a very high level, 70% among the 638 patients with AF in Dunleavy et al.'s investigation. They performed the examinations on low-resolution, 64-slice CT scanners (168). Visual CACS estimation was also used in the study of Hillerson et al., where 60-64% CAC was found on 278 non-gated CT scans retrospectively (169). Cardiac CTA was performed by Kornej et al., where $\geq 75\%$ luminal reduction was defined as clinically relevant stenosis. Out of the 238 AF patients studied, 28% had such stenosis observed (170). In most of the studies, $\geq 50\%$ luminal coronary artery stenosis was identified as CAD: Weijs et al. found underlying CAD in 49% of paroxysmal AF cohort of 390 patients (121), while Nucifora et al. reported similar, 41% obstructive CAD cases among 150 patients with AF using 16- and 64-slice scanners (171). In a recent study involving 94 patients, only 26% had obstructive CAD on a 128-slice CT (120).

In our study, we applied the most widely used definition of CAD ($\geq 50\%$ luminal stenosis). A very high resolution, 256-slice CT-scanner was used, which allows an accurate diagnosis. We observed a relatively high incidence (21%) of coronary artery luminal stenosis in patients a high number of patients without any suspect of CAD (Herczeg et al., 2022, under review).

5.2.3. *RISK FACTORS OF CORONARY ARTERY DISEASE*

There has been a significant literature available on the risk factors for CAD in the AF population. The most often described associated factors are age and male sex (118, 172). Weijs et al. compared 115 paroxysmal AF patients with subjects with constant sinus rhythm. According to their results, besides the above demographic risk factors, the history of AF and prolonged LA diameter are also predictors for luminal stenosis (121). The CADAFA-CT trial identified independent risk factors of myocardial ischemia in 757 AF patients: male sex, high number of co-existing coronary risk factors (hypertension, diabetes, dyslipidaemia, family history of CV disease, history of smoking, BMI $>25\text{kg/m}^2$), elevated BNP levels, enlarged LAV, and elevated CACS (118, 172). In the retrospective study of Rottlander et al. including 566 paroxysmal or newly diagnosed AF patients, diabetes, Framingham score, and CHA₂DS₂-VASc score were also predictors for CAD (165). In contrast, in the report of Chen et al., CACS was seen in patients without any conventional CV risk factors (123).

In our investigation, obstructive CAD was threefold more likely to be present among patients > 65 years old, and nearly twofold more likely to be present in male and in patients with diabetes. Hypertension, dyslipidaemia, and history of smoking were also significant variables anticipating obstructive CAD, similar to the previously presented publications. Surprisingly, positive CV family history and obesity did not show a statistically significant correlation with CAD (Herczeg et al., 2022, under review).

5.2.4. *CLINICAL IMPACT OF PRE-ABLATION CORONARY CT ANGIOGRAPHY*

Our study underlines the importance of coronary artery status characteristics in AF patients. The defined associated factors and relatively high number of novel obstructive CAD suggest that it is beneficial extending the routine pre-ablation left atrial CT examination with characterization for coronary artery stenosis even in case of patients with no chest pain. For AF treatment, the holistic ‘ABC’ pathway is suggested by the European Society of Cardiology’s new prevention guideline (6). The identification and management of concomitant diseases and cardiometabolic risk factors (‘C’) play an equal role as the anticoagulation (‘A’) and better symptom (‘B’) management (6). Since a newly diagnosed obstructive CAD could raise the ischaemic risk of the AF patients, these patients would need a re-evaluation of preventive medical treatment (e.g. statins, antithrombotic therapy), lifestyle changes (e.g. weight loss, the secession of smoking),

reduction of modifiable risk factors (e.g. hypertension, hyperglycaemia), or even further investigations (e.g. stress echocardiography, coronarography) based on other individual risk factors and chronic diseases (6).

Besides, a newly discovered obstructive CAD could make it necessary to recalculate the CHA₂DS₂-VASc score, elevating the risk for thromboembolic events. The change in the score would potentially also modify the anticoagulation strategy in patients with AF. Moreover, a review confirmed that AF patients with obstructive CAD had a higher incidence of thromboembolic events (ischemic stroke and systemic thromboembolism) as compared to subjects adjusted for CHA₂DS₂-VASc score components and relevant variables (173). CHA₂DS₂-VASc reclassification was indicated in 20-50% of AF patients after cardiac CTA examination (120, 123, 174). Anticoagulation treatment was modified in 20% of the cohort according to Wang et al. (174).

6. LIMITATIONS

The main limitation of our first three prospective studies is its single-centre setting with a relatively low number of patients included. However, the overall number of the population was comparable to those reported in the literature. While great effort was taken to minimise this (by re-mapping areas of low voltage with the mapping catheter using the tissue proximity indicator algorithm, and with the ablation catheter using contact force), it is impossible to completely exclude a potential underestimation of the measured voltage through poor contact. Manual registration of each point's voltage and subsequent low voltage area quantification was not part of our protocol, which could be considered as a limitation. The manual exclusion of appendages, pulmonary veins, mitral annulus, vena cava from maps introduces a potential for operator bias or error, and may affect overall accuracy to a limited degree. The potential effect of measuring left atrial voltage during coronary sinus pacing or immediately post AF cardioversion was not taken into consideration. The new VHA Tool had not been released in the commercially available CARTO3[®] EAMS, thus, the use of the software was limited at the time of our publication. Our third study was not designed to evaluate the right atrial low voltage area as a risk factor of AF recurrence post-ablation; a larger scale study would be required to show its clinical impact in that regard.

The most important limitation of our fourth study is its retrospective nature. Unfortunately, there was a significant lack of follow-up of the patients regarding the consequence of the results of the coronary CTA image. Therefore, we could not demonstrate our investigation's ultimate clinical impact. Moreover, some patients were excluded from our study, due to the poor quality caused by tachyarrhythmias, which could be a selection bias.

7. CONCLUSIONS

We analysed LVA in patients with AF with a novel, automated voltage histogram analysis tool, which allowed rapid, detailed, systematic and accurate assessment of Diseased LA Tissue burden ($\leq 0.5\text{mV}$) and Dense LA Scar ($\leq 0.2\text{mV}$) in patients undergoing PVI by creating high-density bipolar voltage maps.

We found that the highest quartile of Diseased LA Tissue burden (Dublin Class IV) predicted the two-year outcome of PVI, while Dense LA Scar showed no predictive value. The usage of AAD did not affect the success rates. Furthermore, arrhythmias in the blanking period do predict the success of ablation in our patient population, but no other baseline clinical parameter does. The application of the Dublin Classification may be a useful clinical tool in predicting recurrent AF post PVI. This finding may help to develop more personalized management for patients after PVI.

We could also determine the LVA in the RA with the help of the VHA tool. We found that the Diseased RA Tissue burden has a strong correlation with the Diseased LA Tissue burden. Our study confirmed previous observations suggesting that the RA is a window of the LA, thus, biatrial remodelling and fibrosis are present in patients with AF.

According to pre-ablation coronary CTA images, we observed a high (21%) incidence of obstructive CAD ($\geq 50\%$ luminal stenosis) among patients awaiting ablation due to AF in our Clinic. Chest pain was not associated with the incidence of obstructive CAD. Our findings suggest that it is beneficial extending the routine pre-ablation cardiac CT with characterization for coronary artery stenosis even for patients experiencing no chest pain, since a newly diagnosed obstructive CAD could raise the ischaemic and thromboembolic risk and alter medical treatment strategies.

To summarize, the most important implications of our study are the following:

1. Dublin Class IV (patients with $>31\%$ of Diseased Left Atrial Tissue ($\leq 0.5\text{mV}$)) predicts the success rate of pulmonary vein isolation in patients with atrial fibrillation. Dense Left Atrial Scar ($\leq 0.2\text{ mV}$) revealed no such predictive value.
2. Diseased Right Atrial Tissue burden has a good correlation with the Diseased Left Atrial Tissue burden.
3. Pre-ablation coronary CT angiography is a useful tool to detect novel obstructive coronary artery disease even in patients without chest pain.

8. SUMMARY

Atrial fibrillation (AF), being the most common cardiac arrhythmia, affects a significant proportion of our population. Due to the complex pathophysiology of AF, the management of these patients, requires a holistic and personalised approach, like the ‘ABC’ pathway suggested by the European Society of Cardiology’s new prevention guideline (6). This recommendation underlines the importance of (‘A’) anticoagulation, (‘B’) better symptom management, and (‘C’) cardiovascular risk factor and comorbidity optimisation.

During my PhD work, I focused on part ‘B’, studying patients undergoing catheter ablation treatment for AF. The quantitative definition of low voltage areas by the novel, automated voltage histogram analysis tool helped us to characterize patients with Dense Left Atrial Scar ($\leq 0.2\text{mV}$) and Diseased Left Atrial Tissue ($\leq 0.5\text{mV}$). Diseased Left Atrial Tissue burden gave us a better understanding of left atrial cardiomyopathy. Also, the percentage of Diseased Left Atrial Tissue correlated with the percentage of Diseased Right Atrial Tissue. Additionally, the Dublin Classification was created by our group for quantifying the Diseased Left Atrial Tissue burden, after a clear association was found between its extent and the success of catheter ablation regardless of antiarrhythmic drug therapy. Patients in Dublin Class IV ($> 31\%$ of $\leq 0.5\text{mV}$) had a significantly higher chance of recurrence. According to our results, the prediction of success of catheter ablation based on the Dublin Classification, should play an important part in the patients’ management, as a more diseased atrial tissue could affect the long-term likelihood of AF cure.

Next, I targeted part ‘C’ of the ‘ABC pathway’, and investigated the role of pre-ablation coronary CT angiography. Analysing more than two-thousand patients’ images, a high incidence (21%) of obstructive coronary artery disease (CAD) was found in AF patients without previously known CAD regardless of reported chest pain. This high incidence confirms that coronary artery diagnostics added important information to the generally used left atrial CT only. Therefore, it could alter the ischemic and thromboembolic risk stratification, and possibly change the holistic management of patients with AF.

In conclusion, defining the factors associated with AF and predictors of success of catheter ablation guides us towards a more personalized and holistic treatment for AF.

9. ÖSSZEFOGLALÁS

A pitvarfibrilláció (PF), mint leggyakoribb szívritmuszavar a populációnk jelentős részét érinti. A ritmuszavar komplex patomechanizmusa végett, a PF menedzsmentje egy holisztikus és személyre szabott megközelítést igényel. Egy ilyen PF kezelési stratégia az „ABC” stratégia, mely az antikoagulációt („A”), a tüneti kezelést („B”), valamint a szív-érrendszeri rizikó faktorok és társbetegségek optimalizálását („C”) emeli ki (6).

A PhD munkám során a „B” részre fókuszálva, a PF ritmuskontroll terápiájaként ismert katéteres abláció vonatkozásait kutattam. Egy új, feszültség térkép alapú, automatizált szoftver által kvantifikáltunk alacsony feszültségű területeket, melyek a pitvar hegesedésének mértékét mutatták. A 0,5 mV alatti feszültségű terület, ún. *Diseased Tissue*, jobban magyarázta a bal pitvari cardiomyopathia jelenségét a 0,2mV határértékű *Dense Scar* csoportosításhoz képest. Továbbá, jó korrelációt mutattunk ki a bal és jobb pitvari hegesedés között. Miután egyértelmű összefüggést mutattunk ki a bal pitvari *Diseased Tissue* kiterjedése és a PF katéteres ablációjának antiaritmikumoktól független sikeressége között, megalkottuk a bal pitvari heges területek új osztályozását, a Dublin Klasszifikációt. A Dublin IV. osztályába tartozó betegeknél ($> 31\%$, $\leq 0,5\text{mV}$) szignifikánsan magasabb volt a PF rekurrencia valószínűsége. Eredményeink alapján a katéteres abláció sikerességének Dublin Klasszifikáción alapuló előrejelzését célszerű lenne a beteg kezelésének részévé tenni, mivel a kiterjedt bal pitvari hegesedés (*Diseased Tissue*) befolyásolhatja a PF hosszú-távú sikeres terápiájának valószínűségét.

Ezt követően az „ABC” stratégia „C” részére összpontosítva a PF ablációt megelőző koronária CT angiographia szerepét vizsgáltam. Kétezer feletti beteg képanyagát elemezve, a betegeknél mellkasi fájdalomtól függetlenül, nagy arányban (21%-ban) találtunk obstruktív koronária betegséget, mely korábban nem volt ismert. Ez a magas előfordulás megerősíti azt a feltételezést, hogy az ablációt megelőző bal pitvari CT angiographia vizsgálatokat érdemes kiegészíteni a koronáriákra kiterjesztett felvételekkel. Hiszen egy újonnan felfedezett koronária betegség megváltoztathatja az iszkémiás és tromboembolikus rizikó stratifikációt, valamint a betegutat is.

Összefoglalva, a pitvarfibrilláció asszociálta faktorok, illetve a katéteres abláció sikerességi prediktorainak meghatározása, a pitvarfibrilláció személyre szabottabb, holisztikus ellátását alapozza meg.

10. REFERENCES

1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, Group ESCSD. (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*, 42: 373-498.
2. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, McManus DD, Ko D, Weng LC, Lunetta KL, Frost L, Benjamin EJ, Trinquart L. (2018) Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. *BMJ*, 361: k1453.
3. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. *Am J Cardiol*, 112: 1142-1147.
4. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. (2013) Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. *Eur Heart J*, 34: 2746-2751.
5. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Cosedis Nielsen J, Curtis AB, Davies DW, Day JD, d'Avila A, Natasja de Groot NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T, Document R. (2018) 2017 HRS/EHRA/ECAS/APHRS/SOLAECE

expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Europace*, 20: e1-e160.

6. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, Societies ESCNC, Group ESCSD. (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*, 42: 3227-3337.
7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*, 137: 263-272.
8. Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL, Jr., Ortel TL, Saxonhouse SJ, Spinler SA. (2017) 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. *J Am Coll Cardiol*, 69: 871-898.
9. Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns H, Eckardt L, Gessler N, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Ng GA, Schnabel RB, Suling A, Szumowski L, Themistoclakis S, Vardas P, van Gelder IC, Wegscheider K, Kirchhof P. (2022) Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. *Eur Heart J*, 43: 1219-1230.
10. Arbelo E, Brugada J, Blomstrom-Lundqvist C, Laroche C, Kautzner J, Pokushalov E, Raatikainen P, Efremidis M, Hindricks G, Barrera A, Maggioni A, Tavazzi L, Dagres N, on the behalf of the ESCAFAAL-tRI. (2017) Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. *Eur Heart J*, 38: 1303-1316.
11. Walfridsson H, Walfridsson U, Nielsen JC, Johannessen A, Raatikainen P, Janzon M, Levin LA, Aronsson M, Hindricks G, Kongstad O, Pehrson S, Englund A,

- Hartikainen J, Mortensen LS, Hansen PS. (2015) Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial. *Europace*, 17: 215-221.
12. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM, Bradley DJ, Bluhm CM, Haroldson JM, Packer DL. (2010) Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. *J Am Coll Cardiol*, 55: 2308-2316.
 13. Guo J, Nayak HM, Besser SA, Beaser A, Aziz Z, Broman M, Ozcan C, Tung R, Upadhyay GA. (2019) Impact of Atrial Fibrillation Ablation on Recurrent Hospitalization: A Nationwide Cohort Study. *JACC Clin Electrophysiol*, 5: 330-339.
 14. Reynolds MR, David G, Gunnarsson C, March JL, Hao SC. (2014) The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation. *J Health Econ Outcomes Res*, 2: 15-28.
 15. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med*, 339: 659-666.
 16. Pappone C, Rosanio S, Oreto G, Tocchi M, Gugliotta F, Vicedomini G, Salvati A, Dicandia C, Mazzone P, Santinelli V, Gulletta S, Chierchia S. (2000) Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. *Circulation*, 102: 2619-2628.
 17. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr., Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D, Heart Rhythm Society Task Force on C, Surgical Ablation of Atrial F. (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design:

a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. *Heart Rhythm*, 9: 632-696 e621.

18. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P, Investigators SAI. (2015) Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med*, 372: 1812-1822.
19. Sawhney N, Anousheh R, Chen W, Feld GK. (2010) Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. *Circ Arrhythm Electrophysiol*, 3: 243-248.
20. Matsuo S, Wright M, Knecht S, Nault I, Lellouche N, Lim KT, Arantes L, O'Neill MD, Hocini M, Jais P, Haissaguerre M. (2010) Peri-mitral atrial flutter in patients with atrial fibrillation ablation. *Heart Rhythm*, 7: 2-8.
21. Scott PA, Silberbauer J, Murgatroyd FD. (2016) The impact of adjunctive complex fractionated atrial electrogram ablation and linear lesions on outcomes in persistent atrial fibrillation: a meta-analysis. *Europace*, 18: 359-367.
22. Kircher S, Arya A, Altmann D, Rolf S, Bollmann A, Sommer P, Dagres N, Richter S, Breithardt OA, Dinov B, Husser D, Eitel C, Gaspar T, Piorkowski C, Hindricks G. (2018) Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study. *Europace*, 20: 1766-1775.
23. Kuck KH, Furnkranz A, Chun KR, Metzner A, Ouyang F, Schluter M, Elvan A, Lim HW, Kueffer FJ, Arentz T, Albenque JP, Tondo C, Kuhne M, Sticherling C, Brugada

- J, Fire, Investigators ICE. (2016) Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. *Eur Heart J*, 37: 2858-2865.
24. Walters TE, Ellims AH, Kalman JM. (2015) The role of left atrial imaging in the management of atrial fibrillation. *Prog Cardiovasc Dis*, 58: 136-151.
 25. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, Healey JS, Natale A, Investigators R-. (2014) Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. *JAMA*, 311: 692-700.
 26. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale A. (2005) Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *JAMA*, 293: 2634-2640.
 27. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. (2009) Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. *Circ Arrhythm Electrophysiol*, 2: 349-361.
 28. Nielsen JC, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Pehrson SM, Englund A, Hartikainen J, Mortensen LS, Hansen PS, Investigators M-P. (2017) Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. *Heart*, 103: 368-376.
 29. Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kenneback G, Rubulis A, Malmborg H, Raatikainen P, Lonnnerholm S, Hoglund N, Mortsell D. (2019) Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. *JAMA*, 321: 1059-1068.
 30. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL, Investigators C. (2019) Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. *JAMA*, 321: 1275-1285.

31. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL, Investigators C. (2019) Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. *JAMA*, 321: 1261-1274.
32. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, Svendsen JH. (2014) Recurrence of arrhythmia following short-term oral AMIODARONE after CATHeter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). *Eur Heart J*, 35: 3356-3364.
33. Duytschaever M, Demolder A, Philips T, Sarkozy A, El Haddad M, Taghji P, Knecht S, Tavernier R, Vandekerckhove Y, De Potter T. (2018) Pulmonary vein isolation With vs. without continued antiarrhythmic Drug treatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. *Eur Heart J*, 39: 1429-1437.
34. Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, Morishima I, Miura F, Watanabe T, Masuda M, Naito M, Fujimoto H, Nishida T, Furukawa Y, Shirayama T, Tanaka M, Okajima K, Yao T, Egami Y, Satomi K, Noda T, Miyamoto K, Haruna T, Kawaji T, Yoshizawa T, Toyota T, Yahata M, Nakai K, Sugiyama H, Higashi Y, Ito M, Horie M, Kusano KF, Shimizu W, Kamakura S, Morimoto T, Kimura T, Shizuta S, Investigators E-AT. (2016) Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. *Eur Heart J*, 37: 610-618.
35. Ebersberger U, Bernard ML, Schoepf UJ, Wince WB, Litwin SE, Wang Y, Blanke P, Makowski MR, McQuiston AD, Silverman JR, Gray JC, Tesche C, Duguay TM, Schmidt M, Wharton JM, Bayer RR, 2nd. (2020) Cardiac Computed Tomography for Atrial Fibrillation Patients Undergoing Ablation: Implications for the Prediction of Early Recurrence. *J Thorac Imaging*, 35: 186-192.
36. Andrade JG, Khairy P, Verma A, Guerra PG, Dubuc M, Rivard L, Deyell MW, Mondesert B, Thibault B, Talajic M, Roy D, Macle L. (2012) Early recurrence of

atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrillation. *Pacing Clin Electrophysiol*, 35: 106-116.

37. Wynn GJ, Das M, Bonnett LJ, Hall MCS, Snowdon RL, Waktare JEP, Modi S, Todd DM, Gupta D. (2015) A novel marker to predict early recurrence after atrial fibrillation ablation: the ablation effectiveness quotient. *J Cardiovasc Electrophysiol*, 26: 397-403.
38. Arya A, Hindricks G, Sommer P, Huo Y, Bollmann A, Gaspar T, Bode K, Husser D, Kottkamp H, Piorkowski C. (2010) Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. *Europace*, 12: 173-180.
39. Liang JJ, Dixit S. (2018) Early Recurrences During the Blanking Period after Atrial Fibrillation Ablation. *J Atr Fibrillation*, 10: 1726.
40. Pokushalov E, Romanov A, Corbucci G, Bairamova S, Losik D, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. (2012) Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? *Heart Rhythm*, 9: 1375-1379.
41. De Pooter J, Strisciuglio T, El Haddad M, Wolf M, Philips T, Vandekerckhove Y, Tavernier R, Knecht S, Duytschaever M. (2019) Pulmonary Vein Reconnection No Longer Occurs in the Majority of Patients After a Single Pulmonary Vein Isolation Procedure. *JACC Clin Electrophysiol*, 5: 295-305.
42. Dagres N, Bongiorni MG, Larsen TB, Hernandez-Madrid A, Pison L, Blomstrom-Lundqvist C, Scientific Initiatives Committee EHRA. (2015) Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. *Europace*, 17: 1596-1600.
43. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, Dubuc M, Reddy V, Nelson L, Holcomb RG, Lehmann JW, Ruskin JN, Investigators SAC. (2013) Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. *J Am Coll Cardiol*, 61: 1713-1723.
44. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA, ThermoCool AFTI. (2010) Comparison of antiarrhythmic

- drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *JAMA*, 303: 333-340.
45. Philips T, Taghji P, El Haddad M, Wolf M, Knecht S, Vandekerckhove Y, Tavernier R, Duytschaever M. (2018) Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the 'CLOSE'-protocol. *Europace*, 20: f419-f427.
 46. Deng H, Shantsila A, Xue Y, Potpara TS, Bai Y, Zhan X, Fang X, Liao H, Wei W, Wu S, Lip GYH. (2018) Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project. *Int J Clin Pract*, 72: e13247.
 47. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T, Roberts-Thomson KC, Sanders P. (2013) Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. *J Am Heart Assoc*, 2: e004549.
 48. Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA, Luker J, Berner I, Schaffer B, Wegscheider K, Lezius S, Willems S, Steven D. (2015) Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. *Circ Arrhythm Electrophysiol*, 8: 308-317.
 49. Mugnai G, Paparella G, Overeinder I, Stroker E, Sieira J, Bisignani A, Iacopino S, Boveda S, Beckers S, Umbrain V, Bala G, Brugada P, de Asmundis C, Chierchia GB. (2021) Long-term clinical outcomes after single freeze cryoballoon ablation for paroxysmal atrial fibrillation: a 5-year follow-up. *J Interv Card Electrophysiol*, 61: 87-93.
 50. Mesquita J, Cavaco D, Ferreira AM, Costa FM, Carmo P, Morgado F, Mendes M, Adragao P. (2018) Very long-term outcomes after a single catheter ablation procedure for the treatment of atrial fibrillation-the protective role of antiarrhythmic drug therapy. *J Interv Card Electrophysiol*, 52: 39-45.
 51. Wynn GJ, El-Kadri M, Haq I, Das M, Modi S, Snowdon R, Hall M, Waktare JE, Todd DM, Gupta D. (2016) Long-term outcomes after ablation of persistent atrial fibrillation: an observational study over 6 years. *Open Heart*, 3: e000394.

52. Steinberg JS, Palekar R, Sichrovsky T, Arshad A, Preminger M, Musat D, Shaw RE, Mittal S. (2014) Very long-term outcome after initially successful catheter ablation of atrial fibrillation. *Heart Rhythm*, 11: 771-776.
53. Tutuianu C, Szilagy J, Pap R, Saghy L. (2015) Very Long-Term Results Of Atrial Fibrillation Ablation Confirm That This Therapy Is Really Effective. *J Atr Fibrillation*, 8: 1226.
54. Sawhney N, Anousheh R, Chen WC, Narayan S, Feld GK. (2009) Five-year outcomes after segmental pulmonary vein isolation for paroxysmal atrial fibrillation. *Am J Cardiol*, 104: 366-372.
55. Teunissen C, Kassenberg W, van der Heijden JF, Hassink RJ, van Driel VJ, Zuithoff NP, Doevendans PA, Loh P. (2016) Five-year efficacy of pulmonary vein antrum isolation as a primary ablation strategy for atrial fibrillation: a single-centre cohort study. *Europace*, 18: 1335-1342.
56. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. (2014) Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol*, 64: 2222-2231.
57. Link MS, Haissaguerre M, Natale A. (2016) Ablation of Atrial Fibrillation: Patient Selection, Periprocedural Anticoagulation, Techniques, and Preventive Measures After Ablation. *Circulation*, 134: 339-352.
58. Glover BM, Hong KL, Dagres N, Arbelo E, Laroche C, Riahi S, Bertini M, Mikhaylov EN, Galvin J, Kiliszek M, Pokushalov E, Kautzner J, Calvo N, Blomstrom-Lundqvist C, Brugada J, investigators E-EAFAL-TR. (2019) Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. *Heart*, 105: 244-250.
59. De Greef Y, Schwagten B, Chierchia GB, de Asmundis C, Stockman D, Buysschaert I. (2018) Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI Registry. *Europace*, 20: 589-595.
60. Kornej J, Schumacher K, Dinov B, Kosich F, Sommer P, Arya A, Husser D, Bollmann A, Lip GYH, Hindricks G. (2018) Prediction of electro-anatomical

substrate and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER scores in patients with atrial fibrillation undergoing catheter ablation. *Sci Rep*, 8: 12686.

61. O'Neill L, Harrison J, O'Neill M, Williams SE. (2017) Clinical, electrophysiological and imaging predictors of atrial fibrillation ablation outcome. *Expert Rev Cardiovasc Ther*, 15: 289-305.
62. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D'Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner DR, Nattel S. (2017) EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. *Heart Rhythm*, 14: e3-e40.
63. Iwasaki YK, Nishida K, Kato T, Nattel S. (2011) Atrial fibrillation pathophysiology: implications for management. *Circulation*, 124: 2264-2274.
64. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorennek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*, 37: 2893-2962.
65. Ma G, Wu X, Zeng L, Jin J, Liu X, Zhang J, Zhang L. (2019) Association of Autoantibodies against M2-Muscarinic Acetylcholine Receptor with Atrial Fibrosis in Atrial Fibrillation Patients. *Cardiol Res Pract*, 2019: 8271871.
66. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O'Neill J, Silva-Cardoso J, Zharinov O, Gamra H, Alam S, Ponikowski P, Lewalter T, Rosenqvist M, Steg PG. (2012) Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey

- evaluating patients with atrial fibrillation international registry. *Circ Arrhythm Electrophysiol*, 5: 632-639.
67. Corradi D, Maestri R, Macchi E, Callegari S. (2011) The atria: from morphology to function. *J Cardiovasc Electrophysiol*, 22: 223-235.
 68. Kottkamp H. (2012) Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. *J Cardiovasc Electrophysiol*, 23: 797-799.
 69. Corradi D, Callegari S, Manotti L, Ferrara D, Goldoni M, Alinovi R, Pinelli S, Mozzoni P, Andreoli R, Asimaki A, Pozzoli A, Becchi G, Mutti A, Benussi S, Saffitz JE, Alfieri O. (2014) Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. *Heart Rhythm*, 11: 1250-1258.
 70. Olsen FJ, Bertelsen L, de Knecht MC, Christensen TE, Vejlstrup N, Svendsen JH, Jensen JS, Biering-Sorensen T. (2016) Multimodality Cardiac Imaging for the Assessment of Left Atrial Function and the Association With Atrial Arrhythmias. *Circ Cardiovasc Imaging*, 9: e004947.
 71. Peters DC, Wylie JV, Hauser TH, Kissinger KV, Botnar RM, Essebag V, Josephson ME, Manning WJ. (2007) Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. *Radiology*, 243: 690-695.
 72. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J. (2014) Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA*, 311: 498-506.
 73. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM, Daccarett M, Windfelder J, McGann CJ, Parker D, MacLeod RS, Marrouche NF. (2009) Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. *Circulation*, 119: 1758-1767.
 74. Mahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT, McGann CJ, Akoum N, Kholmovski E, Macleod RS, Marrouche NF. (2010) Evaluation of the

left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. *Heart Rhythm*, 7: 1475-1481.

75. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, Wilson B, Cates J, Harrison A, Ranjan R, Burgon NS, Greene T, Kim D, Dibella EV, Parker D, Macleod RS, Marrouche NF. (2014) Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. *Circ Arrhythm Electrophysiol*, 7: 23-30.
76. Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S, Rao SN, Blauer J, Fish EN, Dibella EV, Macleod RS, McGann C, Litwin SE, Marrouche NF. (2010) Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. *Circ Cardiovasc Imaging*, 3: 231-239.
77. Zghaib T, Keramati A, Chrispin J, Huang D, Balouch MA, Ciuffo L, Berger RD, Marine JE, Ashikaga H, Calkins H, Nazarian S, Spragg DD. (2018) Multimodal Examination of Atrial Fibrillation Substrate: Correlation of Left Atrial Bipolar Voltage Using Multi-Electrode Fast Automated Mapping, Point-by-Point Mapping, and Magnetic Resonance Image Intensity Ratio. *JACC Clin Electrophysiol*, 4: 59-68.
78. Kuchynka P, Podzimkova J, Masek M, Lambert L, Cerny V, Danek B, Palecek T. (2015) The Role of Magnetic Resonance Imaging and Cardiac Computed Tomography in the Assessment of Left Atrial Anatomy, Size, and Function. *Biomed Res Int*, 2015: 247865.
79. Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M, Mondillo S, Edvardsen T, Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A, Potpara TS, Van Gelder IC, Gorenek B, Mabo P, Lancellotti P, Kuck KH, Popescu BA, Hindricks G, Habib G, Cardim NM, Cosyns B, Delgado V, Haugaa KH, Muraru D, Nieman K, Boriani G, Cohen A. (2016) EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. *Eur Heart J Cardiovasc Imaging*, 17: 355-383.
80. Hunter RJ, Jones DA, Boubertakh R, Malcolm-Lawes LC, Kanagaratnam P, Juli CF, Davies DW, Peters NS, Baker V, Earley MJ, Sporton S, Davies LC, Westwood M, Petersen SE, Schilling RJ. (2013) Diagnostic accuracy of cardiac magnetic

resonance imaging in the detection and characterization of left atrial catheter ablation lesions: a multicenter experience. *J Cardiovasc Electrophysiol*, 24: 396-403.

81. Sramko M, Peichl P, Wichterle D, Tintera J, Weichet J, Maxian R, Pasnisinova S, Kockova R, Kautzner J. (2015) Clinical value of assessment of left atrial late gadolinium enhancement in patients undergoing ablation of atrial fibrillation. *Int J Cardiol*, 179: 351-357.
82. Giannakidis A, Nyktari E, Keegan J, Pierce I, Suman Horduna I, Haldar S, Pennell DJ, Mohiaddin R, Wong T, Firmin DN. (2015) Rapid automatic segmentation of abnormal tissue in late gadolinium enhancement cardiovascular magnetic resonance images for improved management of long-standing persistent atrial fibrillation. *Biomed Eng Online*, 14: 88.
83. Kim YH, Chen SA, Ernst S, Guzman CE, Han S, Kalarus Z, Labadet C, Lin YJ, Lo LW, Nogami A, Saad EB, Sapp J, Sticherling C, Tilz R, Tung R, Kim YG, Stiles MK. (2020) 2019 APHRS expert consensus statement on three-dimensional mapping systems for tachycardia developed in collaboration with HRS, EHRA, and LAHRS. *J Arrhythm*, 36: 215-270.
84. Murgatroyd F, Krahn AD, Klein GJ, Skanes AC, Yee RK. *Handbook of Cardiac Electrophysiology: A Practical Guide to Invasive EP Studies and Catheter Ablation*. Remedica, London, 2003: 1-239.
85. Vlachos K, Efremidis M, Letsas KP, Bazoukis G, Martin R, Kalafateli M, Lioni L, Georgopoulos S, Saplaouras A, Efremidis T, Liu T, Valkanas K, Karamichalakis N, Asvestas D, Sideris A. (2017) Low-voltage areas detected by high-density electroanatomical mapping predict recurrence after ablation for paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol*, 28: 1393-1402.
86. Sim I, Bishop M, O'Neill M, Williams SE. (2019) Left atrial voltage mapping: defining and targeting the atrial fibrillation substrate. *J Interv Card Electrophysiol*, 56: 213-227.
87. Ahmed-Jushuf F, Murgatroyd F, Dhillon P, Scott PA. (2019) The impact of the presence of left atrial low voltage areas on outcomes from pulmonary vein isolation. *J Arrhythm*, 35: 205-214.
88. Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Tsujimura T, Matsuda Y, Okuno S, Ohashi T, Tsuji A, Mano T. (2018) Left atrial low-voltage

- areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal atrial fibrillation. *Int J Cardiol*, 257: 97-101.
89. Wang XH, Li Z, Mao JL, Zang MH, Pu J. (2018) Low voltage areas in paroxysmal atrial fibrillation: The prevalence, risk factors and impact on the effectiveness of catheter ablation. *Int J Cardiol*, 269: 139-144.
 90. Huang D, Li JB, Zghaib T, Gucuk Ipek E, Balouch M, Spragg DD, Ashikaga H, Tandri H, Sinha SK, Marine JE, Berger RD, Calkins H, Nazarian S. (2018) The Extent of Left Atrial Low-Voltage Areas Included in Pulmonary Vein Isolation Is Associated With Freedom from Recurrent Atrial Arrhythmia. *Can J Cardiol*, 34: 73-79.
 91. Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S, Schweikert RA, Saliba W, Cummings J, Burkhardt JD, Bhargava M, Belden WA, Abdul-Karim A, Natale A. (2005) Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. *J Am Coll Cardiol*, 45: 285-292.
 92. Travers J, Keelan E, Keaney J, Szeplaki G, Valentine J, Hayam G, Galvin J. (2016) 96-22: Comparison of a novel tool for automatic measurement of left atrial scar burden with visual estimation in patients undergoing ablation of atrial fibrillation. *EP Europace*, 18: i65-i65.
 93. Maille B, Das M, Hussein A, Shaw M, Chaturvedi V, Morgan M, Ronayne C, Snowdon RL, Gupta D. (2018) Accuracy of left atrial bipolar voltages obtained by ConfiDENSE multielectrode mapping in patients with persistent atrial fibrillation. *J Cardiovasc Electrophysiol*, 29: 881-888.
 94. de Groot NM, Schalij MJ, Zeppenfeld K, Blom NA, Van der Velde ET, Van der Wall EE. (2003) Voltage and activation mapping: how the recording technique affects the outcome of catheter ablation procedures in patients with congenital heart disease. *Circulation*, 108: 2099-2106.
 95. Liang JJ, Elafros MA, Muser D, Pathak RK, Santangeli P, Supple GE, Schaller RD, Frankel DS, Dixit S. (2017) Comparison of Left Atrial Bipolar Voltage and Scar Using Multielectrode Fast Automated Mapping versus Point-by-Point Contact Electroanatomic Mapping in Patients With Atrial Fibrillation Undergoing Repeat Ablation. *J Cardiovasc Electrophysiol*, 28: 280-288.

96. Shen W, Zhai L, Yang G, Liu H, Chen H, Ju W, Gu K, Li M, Zhang F, Chen M. (2018) Efficacy of sole pulmonary vein isolation in patients with nonparoxysmal atrial fibrillation without significant left atrium scar. *Pacing Clin Electrophysiol*, 41: 1356-1361.
97. Akoum N, Wilber D, Hindricks G, Jais P, Cates J, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Hutchinson M, Herweg B, Daoud E, Wissner E, Brachmann J, Marrouche NF. (2015) MRI Assessment of Ablation-Induced Scarring in Atrial Fibrillation: Analysis from the DECAAF Study. *J Cardiovasc Electrophysiol*, 26: 473-480.
98. Nery PB, Al Dawood W, Nair GM, Redpath CJ, Sadek MM, Chen L, Green MS, Wells G, Birnie DH. (2018) Characterization of Low-Voltage Areas in Patients With Atrial Fibrillation: Insights From High-Density Intracardiac Mapping. *Can J Cardiol*, 34: 1033-1040.
99. Akutsu Y, Tanno K, Kobayashi Y. (2012) The Role of Atrial Structural Remodeling in Atrial Fibrillation Ablation: An Imaging Point of View for Predicting Recurrence. *J Atr Fibrillation*, 5: 509.
100. Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D, Piedra C, Hindricks G, Piorkowski C. (2014) Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. *Circ Arrhythm Electrophysiol*, 7: 825-833.
101. Blandino A, Bianchi F, Grossi S, Biondi-Zoccai G, Conte MR, Gaido L, Gaita F, Scaglione M, Rametta F. (2017) Left Atrial Substrate Modification Targeting Low-Voltage Areas for Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta-Analysis. *Pacing Clin Electrophysiol*, 40: 199-212.
102. Yamaguchi T, Tsuchiya T, Nakahara S, Fukui A, Nagamoto Y, Murotani K, Eshima K, Takahashi N. (2016) Efficacy of Left Atrial Voltage-Based Catheter Ablation of Persistent Atrial Fibrillation. *J Cardiovasc Electrophysiol*, 27: 1055-1063.
103. Schreiber D, Rieger A, Moser F, Kottkamp H. (2017) Catheter ablation of atrial fibrillation with box isolation of fibrotic areas: Lessons on fibrosis distribution and extent, clinical characteristics, and their impact on long-term outcome. *J Cardiovasc Electrophysiol*, 28: 971-983.

- 104.Chen J, Yang ZG, Xu HY, Shi K, Long QH, Guo YK. (2017) Assessments of pulmonary vein and left atrial anatomical variants in atrial fibrillation patients for catheter ablation with cardiac CT. *Eur Radiol*, 27: 660-670.
- 105.Szegedi N, Vecsey-Nagy M, Simon J, Szilveszter B, Herczeg S, Kolossvary M, Idelbi H, Osztheimer I, Klaudia Nagy V, Tahin T, Szeplaki G, Delgado V, Bax JJ, Maurovich-Horvat P, Merkely B, Geller L. (2022) Orientation of the right superior pulmonary vein affects outcome after pulmonary vein isolation. *Eur Heart J Cardiovasc Imaging*, 23: 515-523.
- 106.Simon J, El Mahdiui M, Smit JM, Szaraz L, van Rosendael AR, Herczeg S, Zsarnoczay E, Nagy AI, Kolossvary M, Szilveszter B, Szegedi N, Nagy KV, Tahin T, Geller L, van der Geest RJ, Bax JJ, Maurovich-Horvat P, Merkely B. (2022) Left atrial appendage size is a marker of atrial fibrillation recurrence after radiofrequency catheter ablation in patients with persistent atrial fibrillation. *Clin Cardiol*, 45: 273-281.
- 107.Lambert L, Marek J, Fingrova Z, Havranek S, Kuchynka P, Cerny V, Simek J, Burgetova A. (2018) The predictive value of cardiac morphology for long-term outcome of patients undergoing catheter ablation for atrial fibrillation. *J Cardiovasc Comput Tomogr*, 12: 418-424.
- 108.El Mahdiui M, Simon J, Smit JM, Kuneman JH, van Rosendael AR, Steyerberg EW, van der Geest RJ, Szaraz L, Herczeg S, Szegedi N, Geller L, Delgado V, Merkely B, Bax JJ, Maurovich-Horvat P. (2021) Posterior Left Atrial Adipose Tissue Attenuation Assessed by Computed Tomography and Recurrence of Atrial Fibrillation After Catheter Ablation. *Circ Arrhythm Electrophysiol*, 14: e009135.
- 109.Szegedi N, Simon J, Szilveszter B, Sallo Z, Herczeg S, Szaraz L, Kolossvary M, Orban G, Szeplaki G, Nagy KV, Mahdiui ME, Smit JM, Delgado V, Bax JJ, Maurovich-Horvat P, Merkely B, Geller L. (2022) Abutting Left Atrial Appendage and Left Superior Pulmonary Vein Predicts Recurrence of Atrial Fibrillation After Point-by-Point Pulmonary Vein Isolation. *Front Cardiovasc Med*, 9: 708298.
- 110.Di Cori A, Zucchelli G, Faggioni L, Segreti L, De Lucia R, Barletta V, Viani S, Paperini L, Parollo M, Soldati E, Caramella D, Bongiorni MG. (2021) Role of pre-procedural CT imaging on catheter ablation in patients with atrial fibrillation:

- procedural outcomes and radiological exposure. *J Interv Card Electrophysiol*, 60: 477-484.
111. Mosleh W, Sheikh A, Said Z, Ahmed MA, Gadde S, Shah T, Wilson MF, Beck H, Kim C, Sharma UC. (2018) The use of cardiac-CT alone to exclude left atrial thrombus before atrial fibrillation ablation: Efficiency, safety, and cost analysis. *Pacing Clin Electrophysiol*, 41: 727-733.
 112. Ling Z, McManigle J, Zipunnikov V, Pashakhanloo F, Khurram IM, Zimmerman SL, Philips B, Marine JE, Spragg DD, Ashikaga H, Calkins H, Nazarian S. (2015) The association of left atrial low-voltage regions on electroanatomic mapping with low attenuation regions on cardiac computed tomography perfusion imaging in patients with atrial fibrillation. *Heart Rhythm*, 12: 857-864.
 113. Wissner E, Wellnitz CV, Srivathsan K, Scott LR, Altemose GT. (2009) Value of multislice computed tomography angiography of the thorax in preparation for catheter ablation for the treatment of atrial fibrillation: the impact of unexpected cardiac and extracardiac findings on patient care. *Eur J Radiol*, 72: 284-288.
 114. Simon J, Herczeg S, Borzsák S, Csőre J, Kardos AS, Mérges G, Zsarnóczy E, Szegedi N, Boussoussou M, Vattay B, Kolossváry M, Szilveszter B, Gellér L, Merkely B, Maurovich-Horvat P. (2022) Extracardiac findings on cardiac computed tomography in patients undergoing atrial fibrillation catheter ablation. *Imaging*, doi:10.1556/1647.2022.00057.
 115. Sohns C, Sossalla S, Vollmann D, Luethje L, Seegers J, Schmitto JD, Zabel M, Obenauer S. (2011) Extra cardiac findings by 64-multidetector computed tomography in patients with symptomatic atrial fibrillation prior to pulmonary vein isolation. *Int J Cardiovasc Imaging*, 27: 127-134.
 116. Martins RP, Muresan L, Sellal JM, Mandry D, Regent D, Jarmouni S, Groben L, Zinzus PY, Schwartz J, Brembilla-Perrot B, Magnin-Poul I, Andronache M, Aliot E, De Chillou C. (2011) Incidental extracardiac findings in cardiac computed tomography performed before radiofrequency ablation of atrial fibrillation. *Pacing Clin Electrophysiol*, 34: 1665-1670.
 117. Schietinger BJ, Bozlar U, Hagspiel KD, Norton PT, Greenbaum HR, Wang H, Isbell DC, Patel RA, Ferguson JD, Gay SB, Kramer CM, Mangrum JM. (2008) The

- prevalence of extracardiac findings by multidetector computed tomography before atrial fibrillation ablation. *Am Heart J*, 155: 254-259.
118. Antoku Y, Takemoto M, Mito T, Masumoto A, Nozoe M, Tanaka A, Yamamoto Y, Ueno T, Tsuchihashi T. (2020) Evaluation of Coronary Artery Disease in Patients with Atrial Fibrillation by Cardiac Computed Tomography for Catheter Ablation: CADAFF-CT Trial 2. *Intern Med*, 59: 2831-2837.
 119. Dunleavy MP, Guha A, Cardona A, Fortuna C, Daoud EG, Raman SV, Harfi TT. (2020) Prevalence of Coronary Artery Calcification on Pre-Atrial Fibrillation Ablation CT Pulmonary Venograms and its Impact on Selection for Statin Therapy. *J Clin Med*, 9: 1631.
 120. Nuss FMA, Budde RPJ, van Dijkman ED, Musters PJ, Nieman K, Galema TW. (2020) Prognostic Value of Subclinical Coronary Artery Disease in Atrial Fibrillation Patients Identified by Coronary Computed Tomography Angiography. *Am J Cardiol*, 126: 16-22.
 121. Weijs B, Pisters R, Haest RJ, Kragten JA, Joosen IA, Versteysen M, Timmermans CC, Pison L, Blaauw Y, Hofstra L, Nieuwlaet R, Wildberger J, Crijns HJ. (2012) Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. *Heart Rhythm*, 9: 1923-1929.
 122. Koopmann M, Hinrichs L, Olligs J, Lichtenberg M, Eckardt L, Bose D, Mohlenkamp S, Waltenberger J, Breuckmann F. (2018) Cardiac computed tomography in patients with symptomatic new-onset atrial fibrillation, rule-out acute coronary syndrome, but with intermediate pretest probability for coronary artery disease admitted to a chest pain unit. *Eur J Med Res*, 23: 6.
 123. Chen LQ, Tsiamtsiouris E, Singh H, Rapelje K, Weber J, Dey D, Kosmidou I, Levine J, Cao JJ. (2020) Prevalence of Coronary Artery Calcium in Patients With Atrial Fibrillation With and Without Cardiovascular Risk Factors. *Am J Cardiol*, 125: 1765-1769.
 124. Letsas KP, Efremidis M, Giannopoulos G, Deftereos S, Lioni L, Korantzopoulos P, Vlachos K, Xydonas S, Kossyvakis C, Sideris A. (2014) CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation. *Europace*, 16: 202-207.

- 125.Sakhy S, Didier R, Blain M, Leclercq T, Maza M, Artus A, Issa R, Zeller M, Cochet A, Cottin Y, Laurent G. (2021) No impact of sub-clinical coronary artery disease identified by cardiac CT scan on the recurrence of atrial fibrillation after a single ablation procedure. *J Interv Card Electrophysiol*, doi:10.1007/s10840-021-01018-7.
- 126.Liu L, Zhao D, Zhang J, Yang H, Abdu FA, Guo R, Li S, Tang K, Li H, Che W, Xu Y. (2019) Impact of Stable Coronary Artery Disease on the Efficacy of Cryoballoon Ablation for the Atrial Fibrillation. *Am J Med Sci*, 358: 204-211.
- 127.Szegedi N, Szeplaki G, Herczeg S, Tahin T, Sallo Z, Nagy VK, Oszthimer I, Ozcan EE, Merkely B, Geller L. (2019) Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation. *Europace*, 21: 732-737.
- 128.Herczeg S, Walsh K, Keaney JJ, Keelan E, Travers J, Szeplaki G, Galvin J. (2020) Quantitative assessment of left atrial scar using high-density voltage mapping and a novel automated voltage analysis tool. *J Interv Card Electrophysiol*, 59: 5-12.
- 129.Herczeg S, Galvin J, Keaney JJ, Keelan E, Byrne R, Howard C, Geller L, Szeplaki G. (2020) The Value of Voltage Histogram Analysis Derived Right Atrial Scar Burden in the Prediction of Left Atrial Scar Burden. *Cardiol Res Pract*, 2020: 3981684.
- 130.Herczeg S, Keaney JJ, Keelan E, Howard C, Walsh K, Geller L, Szeplaki G, Galvin J. (2021) Classification of Left Atrial Diseased Tissue Burden Determined by Automated Voltage Analysis Predicts Outcomes after Ablation for Atrial Fibrillation. *Dis Markers*, 2021: 5511267.
- 131.Arsanjani R, Flint N, Beigel R, Khachatryan T, Shalev A, Shturman A, Lee C, Rader F, Berman DS, Heo R, Siegel RJ. (2019) Comparison of Accuracy of Left Atrial Area and Volume by Two-dimensional Trans-thoracic Echocardiography Versus Computed Tomography. *Am J Cardiol*, 123: 1180-1184.
- 132.Koka AR, Yau J, Van Why C, Cohen IS, Halpern EJ. (2010) Underestimation of left atrial size measured with transthoracic echocardiography compared with 3D MDCT. *AJR Am J Roentgenol*, 194: W375-381.
- 133.Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing G, American Society of Echocardiography's G, Standards C, European Association of E. (2005)

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr*, 18: 1440-1463.

134. Raff GL, Abidov A, Achenbach S, Berman DS, Boxt LM, Budoff MJ, Cheng V, DeFrance T, Hellinger JC, Karlsberg RP, Society of Cardiovascular Computed T. (2009) SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. *J Cardiovasc Comput Tomogr*, 3: 122-136.
135. Yagishita A, Gimbel JR, S DEO, Manyam H, Sparano D, Cakulev I, Mackall J, Arruda M. (2017) Long-Term Outcome of Left Atrial Voltage-Guided Substrate Ablation During Atrial Fibrillation: A Novel Adjunctive Ablation Strategy. *J Cardiovasc Electrophysiol*, 28: 147-155.
136. Jadidi A, Muller-Edenborn B, Chen J, Keyl C, Weber R, Allgeier J, Moreno-Weidmann Z, Trenk D, Neumann FJ, Lehrmann H, Arentz T. (2018) The Duration of the Amplified Sinus-P-Wave Identifies Presence of Left Atrial Low Voltage Substrate and Predicts Outcome After Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation. *JACC Clin Electrophysiol*, 4: 531-543.
137. Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Sunaga A, Tsujimura T, Matsuda Y, Ohashi T, Uematsu M. (2017) Comparison of Left Atrial Voltage between Sinus Rhythm and Atrial Fibrillation in Association with Electrogram Waveform. *Pacing Clin Electrophysiol*, 40: 559-567.
138. Yagishita A, S DEO, Cakulev I, Gimbel JR, Sparano D, Manyam H, Manrique-Garcia A, Arredondo M, Mackall J, Arruda M. (2016) Correlation of Left Atrial Voltage Distribution Between Sinus Rhythm and Atrial Fibrillation: Identifying Structural Remodeling by 3-D Electroanatomic Mapping Irrespective of the Rhythm. *J Cardiovasc Electrophysiol*, 27: 905-912.
139. Seifert M, Erk J, Heiderfazel S, Georgi C, Keil A, Butter C. (2020) Impact of mapping points in high-density mapping of the left atrium. *J Interv Card Electrophysiol*, 58: 347-353.
140. Jadidi AS, Lehrmann H, Keyl C, Sorrel J, Markstein V, Minners J, Park CI, Denis A, Jais P, Hocini M, Potocnik C, Allgeier J, Hochholzer W, Herrera-Siklody C, Kim S,

- Omri YE, Neumann FJ, Weber R, Haissaguerre M, Arentz T. (2016) Ablation of Persistent Atrial Fibrillation Targeting Low-Voltage Areas With Selective Activation Characteristics. *Circ Arrhythm Electrophysiol*, 9: e002962.
141. Vlachos K, Efremidis M, Letsas KP, Bazoukis G, Martin R, Kalafateli M, Lioni L, Georgopoulos S, Saplaouras A, Efremidis T, Liu T, Valkanas K, Karamichalakis N, Asvestas D, Sideris A. (2017) Low-voltage areas detected by high-density electroanatomical mapping predict recurrence after ablation for paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol*, doi:10.1111/jce.13321.
142. Squara F, Frankel DS, Schaller R, Kapa S, Chik WW, Callans DJ, Marchlinski FE, Dixit S. (2014) Voltage mapping for delineating inexcitable dense scar in patients undergoing atrial fibrillation ablation: a new end point for enhancing pulmonary vein isolation. *Heart Rhythm*, 11: 1904-1911.
143. Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Sunaga A, Tsujimura T, Matsuda Y, Ohashi T, Uematsu M. (2018) An E/e' ratio on echocardiography predicts the existence of left atrial low-voltage areas and poor outcomes after catheter ablation for atrial fibrillation. *Europace*, 20: e60-e68.
144. Huo Y, Gaspar T, Pohl M, Sitzy J, Richter U, Neudeck S, Mayer J, Kronborg MB, Piorkowski C. (2018) Prevalence and predictors of low voltage zones in the left atrium in patients with atrial fibrillation. *Europace*, 20: 956-962.
145. Ammar-Busch S, Buiatti A, Tatzber A, Reents T, Bourier F, Semmler V, Telishevska M, Hessling G, Deisenhofer I. (2020) Predictors of low voltage areas in persistent atrial fibrillation: is it really a matter of time? *J Interv Card Electrophysiol*, 57: 345-352.
146. Takahashi Y, Yamaguchi T, Fukui A, Otsubo T, Hirota K, Kawano Y, Nakashima K, Tahara M, Kitai T, Kawaguchi A, Takahashi N, Node K. (2020) Impact of Renal Dysfunction on Left Atrial Structural Remodeling and Recurrence After Catheter Ablation for Atrial Fibrillation- A Propensity Score Matching Analysis. *Circ J*, 84: 1254-1260.
147. Hojo R, Fukamizu S, Tokioka S, Inagaki D, Kimura T, Takahashi M, Kitamura T, Sakurada H, Hiraoka M. (2021) The coronary artery calcium score correlates with left atrial low-voltage area: Sex differences. *J Cardiovasc Electrophysiol*, 32: 41-48.

148. Matsuda Y, Masuda M, Asai M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Tsujimura T, Okuno S, Tsuji A, Mano T. (2019) Impact of Renal Dysfunction on Left Atrial Low-Voltage Areas in Patients With Atrial Fibrillation. *Circ J*, 83: 985-990.
149. Anter E, Di Biase L, Contreras-Valdes FM, Gianni C, Mohanty S, Tschabrunn CM, Viles-Gonzalez JF, Leshem E, Buxton AE, Kulbak G, Halaby RN, Zimetbaum PJ, Waks JW, Thomas RJ, Natale A, Josephson ME. (2017) Atrial Substrate and Triggers of Paroxysmal Atrial Fibrillation in Patients With Obstructive Sleep Apnea. *Circ Arrhythm Electrophysiol*, 10: e005407.
150. Prabhu S, Voskoboinik A, McLellan AJA, Peck KY, Pathik B, Nalliah CJ, Wong GR, Azzopardi SM, Lee G, Mariani J, Ling LH, Taylor AJ, Kalman JM, Kistler PM. (2018) Biatrial Electrical and Structural Atrial Changes in Heart Failure: Electroanatomic Mapping in Persistent Atrial Fibrillation in Humans. *JACC Clin Electrophysiol*, 4: 87-96.
151. Kiedrowicz RM, Wielusinski M, Wojtarowicz A, Kazmierczak J. (2021) Atrial fibrillation risk scores to evaluate left atrial substrate based on voltage analysis in long-standing persistent type of arrhythmia. *Kardiol Pol*, 79: 525-530.
152. D'Ambrosio G, Romano S, Alothman O, Frommhold M, Borisov G, El Garhy M, Issa K, Penco M, Raffa S, Geller JC. (2020) Computed tomography-derived left atrial volume index, sex, and age to predict the presence and the extent of left atrial low-voltage zones in patients with atrial fibrillation: The ZAQ score. *J Cardiovasc Electrophysiol*, 31: 895-902.
153. Matsuda Y, Masuda M, Asai M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Tsujimura T, Hata Y, Uematsu H, Mano T. (2020) A new clinical risk score for predicting the prevalence of low-voltage areas in patients undergoing atrial fibrillation ablation. *J Cardiovasc Electrophysiol*, 31: 3150-3158.
154. Kornej J, Buttner P, Sommer P, Dagres N, Dinov B, Schumacher K, Bollmann A, Hindricks G. (2019) Prediction of electro-anatomical substrate using APPLE score and biomarkers. *Europace*, 21: 54-59.
155. Kosiuk J, Dinov B, Kornej J, Acou WJ, Schonbauer R, Fiedler L, Buchta P, Myrda K, Gasior M, Polonski L, Kircher S, Arya A, Sommer P, Bollmann A, Hindricks G, Rolf S. (2015) Prospective, multicenter validation of a clinical risk score for left atrial

- arrhythmogenic substrate based on voltage analysis: DR-FLASH score. *Heart Rhythm*, 12: 2207-2212.
156. Winkle RA, Jarman JW, Mead RH, Engel G, Kong MH, Fleming W, Patrawala RA. (2016) Predicting atrial fibrillation ablation outcome: The CAAP-AF score. *Heart Rhythm*, 13: 2119-2125.
 157. Muller-Edenborn B, Moreno-Weidmann Z, Venier S, Defaye P, Park CI, Guerra J, Alonso-Martin C, Bazan V, Vinolas X, Rodriguez-Font E, Garcia BC, Boveda S, Combes S, Albenque JP, Guy-Moyat B, Trenk D, Eichenlaub M, Chen J, Lehrmann H, Neumann FJ, Arentz T, Jadidi A. (2021) Determinants of fibrotic atrial cardiomyopathy in atrial fibrillation. A multicenter observational study of the RETAC (reseau europeen de traitement d'arrhythmies cardiaques)-group. *Clin Res Cardiol*, doi:10.1007/s00392-021-01973-1.
 158. Voskoboinik A, Wong G, Lee G, Nalliah C, Hawson J, Prabhu S, Sugumar H, Ling LH, McLellan A, Morton J, Kalman JM, Kistler PM. (2019) Moderate alcohol consumption is associated with atrial electrical and structural changes: Insights from high-density left atrial electroanatomic mapping. *Heart Rhythm*, 16: 251-259.
 159. Mahajan R, Nelson A, Pathak RK, Middeldorp ME, Wong CX, Twomey DJ, Carbone A, Teo K, Agbaedeng T, Linz D, de Groot JR, Kalman JM, Lau DH, Sanders P. (2018) Electroanatomical Remodeling of the Atria in Obesity: Impact of Adjacent Epicardial Fat. *JACC Clin Electrophysiol*, 4: 1529-1540.
 160. Begg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP, Pepper CB, Rhode K, Lip GYH, Holden AV, Plein S, Tayebjee MH. (2018) Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. *PLoS One*, 13: e0189936.
 161. Moteleb A, Zarif JK, Ali AN. (2018) Incidence of Atrial Fibrosis in Non-Valvular Atrial Fibrillation Patients and its Impact on Recurrence after Pulmonary Vein Antral Isolation. *J Atr Fibrillation*, 11: 1773.
 162. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. (1997) Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation*, 96: 1180-1184.
 163. Xu GJ, Gan TY, Tang BP, Li YD, Guo X, Abudula A, Abutireheman M, Huo Q. (2009) [Differential expression of collagen and matrix metalloproteinases between

- left and right atria in patients with chronic atrial fibrillation.]. *Sheng Li Xue Bao*, 61: 211-216.
164. Prabhu S, Voskoboinik A, McLellan AJA, Peck KY, Pathik B, Nalliah CJ, Wong GR, Azzopardi SM, Lee G, Mariani J, Ling LH, Taylor AJ, Kalman JM, Kistler PM. (2017) A comparison of the electrophysiologic and electroanatomic characteristics between the right and left atrium in persistent atrial fibrillation: Is the right atrium a window into the left? *J Cardiovasc Electrophysiol*, 28: 1109-1116.
 165. Rottlander D, Saal M, Degen H, Godde M, Horlitz M, Haude M. (2021) Diagnostic role of coronary CT angiography in paroxysmal or first diagnosed atrial fibrillation. *Open Heart*, 8: e001638.
 166. Brown AM, Sease KL, Robey JL, Shofer FS, Hollander JE. (2007) The risk for acute coronary syndrome associated with atrial fibrillation among ED patients with chest pain syndromes. *Am J Emerg Med*, 25: 523-528.
 167. Graf S, Khorsand A, Gwechenberger M, Novotny C, Kletter K, Sochor H, Pirich C, Maurer G, Porenta G, Zehetgruber M. (2007) Typical chest pain and normal coronary angiogram: cardiac risk factor analysis versus PET for detection of microvascular disease. *J Nucl Med*, 48: 175-181.
 168. Dunleavy MP, Guha A, Cardona A, Fortuna C, Daoud EG, Raman SV, Harfi TT. (2020) Prevalence of Coronary Artery Calcification on Pre-Atrial Fibrillation Ablation CT Pulmonary Venograms and its Impact on Selection for Statin Therapy. *J Clin Med*, 9.
 169. Hillerson D, Wool T, Ogunbayo GO, Sorrell VL, Leung SW. (2020) Incidental Coronary Artery Calcification and Stroke Risk in Patients With Atrial Fibrillation. *AJR Am J Roentgenol*, 215: 344-350.
 170. Kornej J, Henger S, Seewoster T, Teren A, Burkhardt R, Thiele H, Thiery J, Scholz M. (2020) Prevalence of atrial fibrillation dependent on coronary artery status: Insights from the LIFE-Heart Study. *Clin Cardiol*, 43: 1616-1623.
 171. Nucifora G, Schuijf JD, Tops LF, van Werkhoven JM, Kajander S, Jukema JW, Schreur JH, Heijenbrok MW, Trines SA, Gaemperli O, Turta O, Kaufmann PA, Knuuti J, Schalij MJ, Bax JJ. (2009) Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation. *Circ Cardiovasc Imaging*, 2: 100-106.

- 172.Mito T, Takemoto M, Antoku Y, Masumoto A, Nozoe M, Kinoshita S, Tanaka A, Yamamoto Y, Ueno T, Tsuchihashi T. (2020) Evaluation of coronary artery disease in patients with atrial fibrillation by cardiac computed tomography for catheter ablation: CADAFF-CT trial. *Heart Vessels*, 35: 1037-1043.
- 173.Cho MS, Lee K, Choi KJ, Lee JB, Do U, Kim YN, Kim J, Nam GB, Kim YH. (2019) Thromboembolic Risk of Imaging-Confirmed Coronary Artery Disease Without Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. *Am J Cardiol*, 123: 1287-1292.
- 174.Wang TKM, Chan N, Cremer PC, Kanj M, Baranowski B, Saliba W, Wazni OM, Jaber WA. (2021) Incorporating coronary calcification by computed tomography into CHA2DS2-VASc score: impact on cardiovascular outcomes in patients with atrial fibrillation. *Europace*, 23: 1211-1218.

11. BIBLIOGRAPHY OF THE CANDIDATE'S PUBLICATION

11.1. BIBLIOGRAPHY RELATED TO THE PRESENT THESIS

1. Herczeg S, Keaney JJ, Keelan E, Howard C, Walsh K, Geller L, Szeplaki G, Galvin J. (2021) Classification of Left Atrial Diseased Tissue Burden Determined by Automated Voltage Analysis Predicts Outcomes after Ablation for Atrial Fibrillation. *Dis Markers*, 2021: 5511267.
IF: 3.464
2. Herczeg S, Walsh K, Keaney JJ, Keelan E, Travers J, Szeplaki G, Galvin J. (2020) Quantitative assessment of left atrial scar using high-density voltage mapping and a novel automated voltage analysis tool. *J Interv Card Electrophysiol*, 59: 5-12.
IF: 1.900
3. Herczeg S, Galvin J, Keaney JJ, Keelan E, Byrne R, Howard C, Geller L, Szeplaki G. (2020) The Value of Voltage Histogram Analysis Derived Right Atrial Scar Burden in the Prediction of Left Atrial Scar Burden. *Cardiol Res Pract*, 2020: 3981684.
IF: 1.866
4. Herczeg S, Simon J, Szegedi N, Karady J, Kolossváry M, Szilveszter B, Balogi B, Nagy KV, Merkely B, Szeplaki G, Maurovich-Horvat P, Geller L. High incidence of newly diagnosed obstructive coronary artery disease regardless of chest pain detected on pre-procedural cardiac CT angiography in patients undergoing atrial fibrillation ablation (2022, under review)

11.2. BIBLIOGRAPHY NOT RELATED TO THE PRESENT THESIS

5. Abraham P, Ambrus M, Herczeg S, Szegedi N, Nagy KV, Sallo Z, Perge P, Osztheimer I, Szeplaki G, Tahin T, Merkely B, Geller L. (2022) Selection of an impedance- or magnetic field-based electro-anatomical mapping platform does not affect outcomes of outflow tract premature ventricular complex manual ablation. *Heart Vessels*, doi:10.1007/s00380-022-02081-4, 7 p.
IF: 1.814[#]
6. Szegedi N, Simon J, Szilveszter B, Sallo Z, Herczeg S, Szaraz L, Kolossvary, Orban G, Szeplaki G, Nagy KV, Mahdiui ME, Smit JM, Delgado V, Bax JJ, Maurovich-Horvat P, Merkely B, Geller L. (2022) Abutting Left Atrial Appendage and Left Superior Pulmonary Vein Predicts Recurrence of Atrial Fibrillation After Point-by-

Point Pulmonary Vein Isolation. *Front Cardiovasc Med*, 9: 708298
IF: 5.846[#]

7. Simon J, Herczeg S, Borzsák S, Csőre J, Kardos AS, Mérges G, Zsarnóczy E, Szegedi N, Boussoussou M, Vattay B, Kolossváry M, Szilveszter B, Geller L, Merkely B, Maurovich-Horvat P. (2022) Extracardiac findings on cardiac computed tomography in patients undergoing atrial fibrillation catheter ablation. *Imaging*, doi:10.1556/1647.2022.00057, 8 p.
8. Szegedi N, Vecsey-Nagy M, Simon J, Szilveszter B, Herczeg S, Kolossvary M, Idelbi H, Osztheimer I, Klaudia Nagy V, Tahin T, Szeplaki G, Delgado V, Bax JJ, Maurovich-Horvat P, Merkely B, Geller L. (2022) Orientation of the right superior pulmonary vein affects outcome after pulmonary vein isolation. *Eur Heart J Cardiovasc Imaging*, 23: 515-523.
IF: 9.130[#]
9. Simon J, El Mahdiui M, Smit JM, Szaraz L, van Rosendael AR, Herczeg S, Zsarnoczay E, Nagy AI, Kolossvary M, Szilveszter B, Szegedi N, Nagy KV, Tahin T, Geller L, van der Geest RJ, Bax JJ, Maurovich-Horvat P, Merkely B. (2022) Left atrial appendage size is a marker of atrial fibrillation recurrence after radiofrequency catheter ablation in patients with persistent atrial fibrillation. *Clin Cardiol*, 45: 273-281.
IF: 3.287[#]
10. El Mahdiui M, Simon J, Smit JM, Kuneman JH, van Rosendael AR, Steyerberg EW, van der Geest RJ, Szaraz L, Herczeg S, Szegedi N, Geller L, Delgado V, Merkely B, Bax JJ, Maurovich-Horvat P. (2021) Posterior Left Atrial Adipose Tissue Attenuation Assessed by Computed Tomography and Recurrence of Atrial Fibrillation After Catheter Ablation. *Circ Arrhythm Electrophysiol*, 14: e009135.
IF: 7.718
11. Audam TN, Howard CM, Garrett LF, Zheng YW, Bradley JA, Brittian KR, Frank MW, Fulghum KL, Polos M, Herczeg S, Merkely B, Radovits T, Uchida S, Hill BG, Dassanayaka S, Jackowski S, Jones SP. (2021) Cardiac PANK1 deletion exacerbates ventricular dysfunction during pressure overload. *Am J Physiol Heart Circ Physiol*, 321: H784-H797.
IF: 5.124

12. Abraham P, Ambrus M, Herczeg S, Szegedi N, Nagy KV, Sallo Z, Osztheimer I, Szeplaki G, Tahin T, Merkely B, Geller L. (2021) Similar outcomes with manual contact force ablation catheters and traditional catheters in the treatment of outflow tract premature ventricular complexes. *Europace*, 23: 596-602.
IF: 5.486
13. Tahin T*, Herczeg S*, Geller L, Boros AM, Kovacs OM, Szegedi N, Forizs E, Szilagyi S, Osztheimer I, Merkely B, Szeplaki G. (2019) [Assessment of the extent of myocardial necrosis following radiofrequency catheter ablation of different supraventricular arrhythmias]. *Orv Hetil*, 160: 540-548.
IF: 0.497
14. Szegedi N, Szeplaki G, Herczeg S, Tahin T, Sallo Z, Nagy VK, Osztheimer I, Ozcan EE, Merkely B, Geller L. (2019) Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation. *Europace*, 21: 732-737.
IF: 4.045
15. Piros K; Nagy KV; Szegedi N; Osztheimer I; Sallo Z; Perge P; Herczeg S; Merkely B; Geller L. (2019) Atrio-ventricular reentry tachycardia, without involvement of the AV node – dual accessory pathway in young, otherwise healthy patient. *Cardiologia Hungarica*, 49: 178-183.
16. Geller L, Sallo Z, Molnar L, Tahin T, Ozcan EE, Kutyifa V, Osztheimer I, Szilagyi S, Szegedi N, Abraham P, Apor A, Nagy KV, Kosztin A, Becker D, Herczeg S, Zima E, Merkely B. (2019) Long-term single-centre large volume experience with transseptal endocardial left ventricular lead implantation. *Europace*, 21: 1237-1245.
IF: 4.045
17. Piros K, Herczeg S; Szegedi N; Sallo Z; Osztheimer I; Szeplaki G; Tahin T; Nagy KV; Perge P; Bettenbuch T; Srej M; Merkely B; Geller L. (2017) With the implementation of ALARA principles the fluoroscopy time can be reduced in a high progressivity center. *Cardiologia Hungarica*, 47: 179-184.

*co-first authorship

#expected IF value

12. ACKNOWLEDGEMENTS

I would like to express my sincere gratitude to my PhD supervisor, Prof Dr László Gellér for giving me the opportunity to conduct scientific and clinical work at the Electrophysiology Laboratory of the Heart and Vascular Centre of Semmelweis University, being a member of a truly encouraging, hard-working and warm-hearted team. His passion for cardiology, as well as gastronomy, will always inspire me in the future. I am thankful for all the support he gave me to widen my horizons during several international congresses and the short-term research work in Dublin, Ireland.

The completion of my scientific work could not have been possible without the wise guidance and innovative ideas of my mentor, Prof Dr Gábor Széplaki. He accompanied me from the very beginning of my research work, showing the beauty of science with his immense knowledge, giving ingenious advices for my scientific, clinical and personal life as well as, and motivating me through hard times during my studies. I am more than grateful for having the opportunity to join the Electrophysiology Laboratory at the Mater Misericordiae University Hospital and Mater Private Hospital in Dublin. It was one of the best lifetime experiences I have had.

I am especially grateful to Prof Dr Béla Merkely for all the intellectual and material circumstances he provided me at the Heart and Vascular Centre of Semmelweis University. Prof Dr Béla Merkely, being the Rector of the Semmelweis University and the Chairman of the Heart and Vascular Centre, guarantees to help every researcher to fulfil their scientific and clinical dreams.

I would like to thank for the guidance and endless support of Dr Nándor Szegedi and Dr István Osztheimer. Also, I am very thankful for all the hard work and support of the whole Electrophysiology Team, including Dr Vivien Klaudia Nagy, Dr Zoltán Salló, Dr Katalin Piros, Dr Tamás Tahin, Dr Pál Ábrahám, Mariann Srej, Tünde Bettenbuch and all the other colleagues.

I would like to give special thanks to Dr Bálint Lakatos, my former PhD-fellow, for his friendship, optimistic and humorous attitude and wise advice and help with scientific and clinical questions and other life-saving issues. I am especially thankful for him

introducing me to the magic of echocardiography along with Dr Attila Kovács and the Echocardiography Team.

I am also incredibly grateful for my former PhD-fellows, Dr Péter Perge, Dr András Mihály Boros, Dr Mihály Ruppert, Dr Miklós Vértes, Dr Csilla Czimbalmos, and for my colleagues, Dr Roland Papp, Dr Zoltan Tarjanyi, Dr Timea Szigethi and many other residents, consultants, nurses and assistants at Heart and Vascular Centre of Semmelweis University for their help and useful advice they gave me any time needed.

I am thankful to the whole MTA-SE Cardiovascular Imaging Research Group for the high-level collaboration, particularly to Dr Judit Simon, Dr Júlia Karády and Dr Pál Maurovich-Horvat.

I am grateful to the whole Electrophysiology Laboratory at the Mater Misericordiae University Hospital and Mater Private Hospital in Dublin for the warm welcome and unconditional trust, as well as the opportunity to be part of an inspiring research and clinical work. I am particularly thankful to Dr Joseph Galvin, Dr Derek Crinion, Dr John Keeney, Dr Katie Walsh, Dr Roger Byrne, Laura Deery and Claire Howard.

Last but not least I would like to express my sincere gratitude to my parents and my sister, who endlessly supported me during my studies. Without their patient guidance and life-time experiences gained together, I wouldn't be at this point. I am also incredibly thankful for my partner, Balazs, whose optimism and constant self-developing attitude always lead me to dream bigger.